CA3156264A1 - Utilization of an agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children - Google Patents
Utilization of an agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children Download PDFInfo
- Publication number
- CA3156264A1 CA3156264A1 CA3156264A CA3156264A CA3156264A1 CA 3156264 A1 CA3156264 A1 CA 3156264A1 CA 3156264 A CA3156264 A CA 3156264A CA 3156264 A CA3156264 A CA 3156264A CA 3156264 A1 CA3156264 A1 CA 3156264A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- agent
- cov2
- cov
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000315672 SARS coronavirus Species 0.000 title claims abstract description 25
- 230000036039 immunity Effects 0.000 title claims description 30
- 230000006698 induction Effects 0.000 title claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 180
- 230000014509 gene expression Effects 0.000 claims abstract description 102
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 93
- 241000598171 Human adenovirus sp. Species 0.000 claims abstract description 60
- 239000013604 expression vector Substances 0.000 claims abstract description 42
- 241000990167 unclassified Simian adenoviruses Species 0.000 claims abstract description 29
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 12
- 239000000872 buffer Substances 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 210000004400 mucous membrane Anatomy 0.000 claims description 10
- 238000007918 intramuscular administration Methods 0.000 claims description 9
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 9
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000016379 mucosal immune response Effects 0.000 claims description 7
- 230000028993 immune response Effects 0.000 abstract description 21
- 238000006243 chemical reaction Methods 0.000 abstract description 18
- 238000011161 development Methods 0.000 abstract description 11
- 230000028996 humoral immune response Effects 0.000 abstract description 9
- 230000004044 response Effects 0.000 abstract description 5
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 63
- 102100031673 Corneodesmosin Human genes 0.000 description 61
- 108090000623 proteins and genes Proteins 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 44
- 230000008488 polyadenylation Effects 0.000 description 37
- 230000001900 immune effect Effects 0.000 description 35
- 230000003053 immunization Effects 0.000 description 29
- 238000002649 immunization Methods 0.000 description 29
- 229960005486 vaccine Drugs 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 239000000427 antigen Substances 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 230000002062 proliferating effect Effects 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 238000012217 deletion Methods 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 239000008177 pharmaceutical agent Substances 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 208000025721 COVID-19 Diseases 0.000 description 14
- 241000701242 Adenoviridae Species 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 108700010877 adenoviridae proteins Proteins 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- 210000004789 organ system Anatomy 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 238000000585 Mann–Whitney U test Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007969 cellular immunity Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 229940022962 COVID-19 vaccine Drugs 0.000 description 4
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002270 exclusion chromatography Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 2
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 2
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 2
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 2
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 2
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 2
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 2
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 2
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 2
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 2
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 2
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 2
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 2
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 2
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 2
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 2
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 2
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 2
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 2
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 2
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 2
- 241000205701 Human adenovirus 26 Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 229940024452 Janssen COVID-19 vaccine Drugs 0.000 description 2
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 2
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 2
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 2
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 2
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 2
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 2
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 101710087110 ORF6 protein Proteins 0.000 description 2
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 2
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 2
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 2
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 2
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 2
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 2
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 2
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 2
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 2
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 2
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 2
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 2
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 2
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004687 hexahydrates Chemical class 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003720 plasmablast Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012770 revaccination Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000037403 Blood and lymphatic system disease Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000036010 Ear and labyrinth disease Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000035451 General disorders and administration site conditions Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000010670 Hemic and Lymphatic disease Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- -1 Magnesium Sodium Ethanol Chemical compound 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940025109 Oxford–AstraZeneca COVID-19 vaccine Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000033475 Renal and urinary disease Diseases 0.000 description 1
- 208000032327 Respiratory, thoracic and mediastinal disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 229940038694 mRNA-based vaccine Drugs 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The group of inventions relates to biotechnology, immunology and virology and, in particular, an agent for prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older. For this purpose there were developed 6 variants of utilization of the agent including component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or component 3 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3. The claimed components are used both individually and in combination. The group of inventions provides for creation of a safe and effective agent enabling development of reactions of humoral and cell immune response to SARS-CoV-2 virus in children aged 1 month and older. Also, the agent induces humoral immune response comparable to an adult's immune response and induces enhanced mucosal response in the respiratory tract..
Description
li0J1Y11 EHO
UTILIZATION OF AN AGENT FOR INDUCTION OF SPECIFIC IMMUNITY
IN CHILDREN
Field of the invention The invention relates to biotechnology, immunology and virology. The claimed agent can be used for prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.
Background of the invention In December 2019 a new coronavirus of zoonotic origin named SARS-CoV-2 spread in Hubei Province, People's Republic of China. The epidemic disease caused by SARS-CoV-2 is called coronavirus disease-19, abbreviated as COVID-19. The given disease can proceed both in an asymptomatic and mild form and in a severe form that can be accompanied with sepsis and multiple organ system failure. Within several months the disease spread all over the world, affecting more than 200 countries. In January 2020, the World Health Organization declared the SARS-CoV-2-related outbreak to be a public health emergency of international concern and in March it described the spread of the disease as a pandemic. By July 28, 2021, over 195 million cases of illness were confirmed and 4 million people died.
The lasting outbreak of COVID-19 poses an ultimate threat for public health.
At present, developing a safe and effective vaccine against SARS-CoV-2 is a most important global priority.
Within the year after the pandemic beginning different pharmaceutical companies offered their variants of a candidate vaccine against COVID-19.
The pharmaceutical company Pfizer, in cooperation with the biotechnology company BioNTech, developed the BNT162b2 vaccine (tozinameran). The given vaccine represents lipid nanoparticles with encapsulated modified mRNA encoding the SARS-CoV-2 S-protein mutant form. At the moment it is allowed to use this vaccine for adults and children aged 12 years and older (F.P. Polacketal. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl Med 2020; 383: 2603-2615;
www.cdc.govicoronavirus/2019-ncov/vaccinestrecommendations/adolescents.html).
Date Recue/Date Received 2022-04-06 The pharmaceutical company Modena, in cooperation with the National Institute of Health (USA), developed the mRNA-1273 vaccine. The active component of this vaccine is mRNA encoding SARS-CoV-2 S protein, which is surrounded with a lipid coating.
At present, urgent use of this vaccine is allowed for adults aged 18 years and older.
Also, Modena carried out a study for children aged 12-17 years, which is now under review. At the moment, a clinical study is under way that is called KidCOVE, in which children aged 6 months -12 years are immunized (L. A. Jackson etal. An mRNA Vaccine against SARS-CoV-2 ¨
Preliminary Report. N Engl J Med 2020; 383:1920-1931;https://penntoday.upenn.edu/news/covid-vaccine-kids; https://clinicaltrials.govict2/show/NCT04796896).
The University of Oxford, in cooperation with the pharmaceutical company AstraZeneca, developed the ChAdOxl nCoV-19 vector vaccine (AZD1222). The active component of this ' vaccine is chimpanzee adenovirus ChAdOxl, including the codon-optimized encoding sequence of full-length S protein of SARS-CoV-2 virus (GenBank MN908947) with the tissue plasminogen activator leader sequence. The vaccination protocol includes double immunization with an interval of 28 days (M. Voysey et al. Safety and efficacy of the ChAdOx 1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. TheLancet. Vol. 397, Issue 10269, P99-111, 2021).
CanSino Company developed a vector vaccine against COVID-19, based on recombinant human adenovirus serotype 5 (Ad5) expressing SARS-CoV-2 full-length S-glycoprotein. At present, the vaccine is intended for urgent use in adults aged 18 years or older.
(GenBankYP 009724390) (Feng-Cai Zhu et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Vol.
369, Issue 10249, P479-488, 2020).
Johnson and Johnson and Janssen Pharmaceutical Research groups, in cooperation with Beth Israel Deaconess Medical Center, implemented the technology JanssenAdVac to create several candidate vaccines. After conducted safety and effectiveness studies the candidate vaccine Ad26.COV2.S was selected (Ad26COVS1). The active component of this vaccine is recombinant adenovirus vector serotype 26 with deletion of El and E3 region, comprising the SARS-CoV-2 S-protein gene, with furin cleavage site mutation and with two proline-stabilizing mutations. The vaccine may be utilized in urgent conditions for adults aged 18 years or older.
Currently there are ongoing studies of vaccine utilization in teenagers and children from birth.
(J. Sadoff et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N
UTILIZATION OF AN AGENT FOR INDUCTION OF SPECIFIC IMMUNITY
IN CHILDREN
Field of the invention The invention relates to biotechnology, immunology and virology. The claimed agent can be used for prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.
Background of the invention In December 2019 a new coronavirus of zoonotic origin named SARS-CoV-2 spread in Hubei Province, People's Republic of China. The epidemic disease caused by SARS-CoV-2 is called coronavirus disease-19, abbreviated as COVID-19. The given disease can proceed both in an asymptomatic and mild form and in a severe form that can be accompanied with sepsis and multiple organ system failure. Within several months the disease spread all over the world, affecting more than 200 countries. In January 2020, the World Health Organization declared the SARS-CoV-2-related outbreak to be a public health emergency of international concern and in March it described the spread of the disease as a pandemic. By July 28, 2021, over 195 million cases of illness were confirmed and 4 million people died.
The lasting outbreak of COVID-19 poses an ultimate threat for public health.
At present, developing a safe and effective vaccine against SARS-CoV-2 is a most important global priority.
Within the year after the pandemic beginning different pharmaceutical companies offered their variants of a candidate vaccine against COVID-19.
The pharmaceutical company Pfizer, in cooperation with the biotechnology company BioNTech, developed the BNT162b2 vaccine (tozinameran). The given vaccine represents lipid nanoparticles with encapsulated modified mRNA encoding the SARS-CoV-2 S-protein mutant form. At the moment it is allowed to use this vaccine for adults and children aged 12 years and older (F.P. Polacketal. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl Med 2020; 383: 2603-2615;
www.cdc.govicoronavirus/2019-ncov/vaccinestrecommendations/adolescents.html).
Date Recue/Date Received 2022-04-06 The pharmaceutical company Modena, in cooperation with the National Institute of Health (USA), developed the mRNA-1273 vaccine. The active component of this vaccine is mRNA encoding SARS-CoV-2 S protein, which is surrounded with a lipid coating.
At present, urgent use of this vaccine is allowed for adults aged 18 years and older.
Also, Modena carried out a study for children aged 12-17 years, which is now under review. At the moment, a clinical study is under way that is called KidCOVE, in which children aged 6 months -12 years are immunized (L. A. Jackson etal. An mRNA Vaccine against SARS-CoV-2 ¨
Preliminary Report. N Engl J Med 2020; 383:1920-1931;https://penntoday.upenn.edu/news/covid-vaccine-kids; https://clinicaltrials.govict2/show/NCT04796896).
The University of Oxford, in cooperation with the pharmaceutical company AstraZeneca, developed the ChAdOxl nCoV-19 vector vaccine (AZD1222). The active component of this ' vaccine is chimpanzee adenovirus ChAdOxl, including the codon-optimized encoding sequence of full-length S protein of SARS-CoV-2 virus (GenBank MN908947) with the tissue plasminogen activator leader sequence. The vaccination protocol includes double immunization with an interval of 28 days (M. Voysey et al. Safety and efficacy of the ChAdOx 1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. TheLancet. Vol. 397, Issue 10269, P99-111, 2021).
CanSino Company developed a vector vaccine against COVID-19, based on recombinant human adenovirus serotype 5 (Ad5) expressing SARS-CoV-2 full-length S-glycoprotein. At present, the vaccine is intended for urgent use in adults aged 18 years or older.
(GenBankYP 009724390) (Feng-Cai Zhu et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Vol.
369, Issue 10249, P479-488, 2020).
Johnson and Johnson and Janssen Pharmaceutical Research groups, in cooperation with Beth Israel Deaconess Medical Center, implemented the technology JanssenAdVac to create several candidate vaccines. After conducted safety and effectiveness studies the candidate vaccine Ad26.COV2.S was selected (Ad26COVS1). The active component of this vaccine is recombinant adenovirus vector serotype 26 with deletion of El and E3 region, comprising the SARS-CoV-2 S-protein gene, with furin cleavage site mutation and with two proline-stabilizing mutations. The vaccine may be utilized in urgent conditions for adults aged 18 years or older.
Currently there are ongoing studies of vaccine utilization in teenagers and children from birth.
(J. Sadoff et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N
2 Date Recue/Date Received 2022-04-06 Engl J Med, 2021 Jan 13.D01: 10.1056 NEJMoa2034201;
haps ://www.janssenmd .com/j anssen-covid19-vaccine/special-populations/pediatrics/use-of-j anssen-covid19-vaccine-in-pediatric-participants).
At Beijing Institute of Biological Products Co. they developed an inactivated vaccine against COVID-19. Emergency use of this vaccine is allowed in adults aged 18 years or older.
Also, there is published information about a clinical study of this vaccine for children in age groups of 3-6 years, 7-12 years, 13-17 years. Currently, the study is going on (https ://www.who int/news/item/07-05-2021-who-lists-additional-covid- 19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations; https ://clinicaltrials .gov /ct2/show/NCT04917523?cond=covid-19+vaccine&age_v=5&draw=2&rank=10).
Thus, at present, only one mRNA-based vaccine against COVID-19 (Pfizer) is approved for use in children. However, doctors observe that the number of young patients hospitalized with COVID-19 diagnosis increases. The mortality among young population increases, too (https://www.paho.org/en/news/5-5-2021-hospitalizations-and-deaths-vounger-people-soar-due-covid-19-paho-director-reports), which raises the need in vaccines for prevention of COVID-19 in children.
Protective immunity against SARS-CoV-2 coronavinis activates several chains of the immune system. It seems that an effective vaccine against COVID-19 shall induce both humoral and cell immune response. Besides, an important element of protective immunity shall be activation of mucosal immunity (for instance, the one implemented via expression of IgA
antibodies) in the nasopharynx, which is the virus penetration gate.
Thus, in the background of the invention there is a need in development of new agents capable of inducing the immune response against SARS-CoV-2 in children, including the mucous membranes of the respiratory tract, which are the main infection gates.
Implementation of the invention The technical task of the claimed group of inventions is creation of agents for effective induction of immune response (including mucosal immune response) against the SARS-CoV-2 virus in children aged 1 month and older.
The technical result consists in creation of a safe and effective agent enabling development of reactions of humoral and cell immune response against the SARS-CoV-2
haps ://www.janssenmd .com/j anssen-covid19-vaccine/special-populations/pediatrics/use-of-j anssen-covid19-vaccine-in-pediatric-participants).
At Beijing Institute of Biological Products Co. they developed an inactivated vaccine against COVID-19. Emergency use of this vaccine is allowed in adults aged 18 years or older.
Also, there is published information about a clinical study of this vaccine for children in age groups of 3-6 years, 7-12 years, 13-17 years. Currently, the study is going on (https ://www.who int/news/item/07-05-2021-who-lists-additional-covid- 19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations; https ://clinicaltrials .gov /ct2/show/NCT04917523?cond=covid-19+vaccine&age_v=5&draw=2&rank=10).
Thus, at present, only one mRNA-based vaccine against COVID-19 (Pfizer) is approved for use in children. However, doctors observe that the number of young patients hospitalized with COVID-19 diagnosis increases. The mortality among young population increases, too (https://www.paho.org/en/news/5-5-2021-hospitalizations-and-deaths-vounger-people-soar-due-covid-19-paho-director-reports), which raises the need in vaccines for prevention of COVID-19 in children.
Protective immunity against SARS-CoV-2 coronavinis activates several chains of the immune system. It seems that an effective vaccine against COVID-19 shall induce both humoral and cell immune response. Besides, an important element of protective immunity shall be activation of mucosal immunity (for instance, the one implemented via expression of IgA
antibodies) in the nasopharynx, which is the virus penetration gate.
Thus, in the background of the invention there is a need in development of new agents capable of inducing the immune response against SARS-CoV-2 in children, including the mucous membranes of the respiratory tract, which are the main infection gates.
Implementation of the invention The technical task of the claimed group of inventions is creation of agents for effective induction of immune response (including mucosal immune response) against the SARS-CoV-2 virus in children aged 1 month and older.
The technical result consists in creation of a safe and effective agent enabling development of reactions of humoral and cell immune response against the SARS-CoV-2
3 Date Recue/Date Received 2022-04-06 virus in children aged 1 month and older.
A child is born with an immature congenital and adaptive immune system that develops and acquires memory with the child's growth. From human birth till puberty the immune system undergoes several stages in its development.
A newborn's immune system is in suppression. The phagocytosis system is not developed. Neonatal T-cells greatly differ from adult cells, which is a consequence of antenatal life, when the impact of nonshared antigens is significantly limited by maternal alloantigens.
Therefore, the very early adaptive T-cell immunity is characterized with tolerogenic reactivity, decreased alloantigen recognition and weak responses to nonshared antigens.
Newborns' B-cells greatly differ from an adult's B-cells, too. Neonatal B-cells are known to have decreased TACI, BCMA and BAFF-R expression as well as decreased IgG and IgA production in response to CD4OL and IL-10 (Kaur K, Chowdhury S, Greenspan NS, Schreiber JR. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood. 2007 Oct 15;110(8):2948-54. doi: 10.1182/blood-2007-01-069245. Epub 2007 Jul 18. PMID: 17634409). Together, these peculiarities contribute to depression of humoral immune responses with incomplete switching of the class of immunoglobulins. B-cells of newborns and infants under 2 months demonstrate reduction of somatic hypermutation comparing to adults, which limits affinity maturation of antibodies. Also, stromal cells of bone marrow at early life stages are incapable of supporting long-term survival of plasmablasts and differentiation into plasma cells, so any IgG antibodies produced after immunization quickly decrease, in distinction to children of older age and adults (Pihlgren M, Friedli M, Tougne C, Rochat AF, Lambert PH, Siegrist CA. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol. 2006 Jan 1;176(1):165-72. doi:
10.4049/jimmuno1.176.1.165. PMID: 16365407). As a result, effectiveness of an adaptive immune system as regards early response to T-cell-dependent antigens is much lower in neonatals comparing to children of older age and adults (A.K. Simon, G.A.
Hollander, A.
McMichael. Evolution of the immune system in humans from infancy to old age.
Proc Biol Sci.
2015 Dec 22; 282(1821): 20143085. doi: 10.1098/rspb.2014.3085, PMCID:
PMC4707740, PMID: 26702035).
In infancy the immune system matures gradually. The critically important early protection against many infectious diseases the mother recovered from earlier is provided by passive IgG antibodies transferred from the mother transplacentally and with milk.
A child is born with an immature congenital and adaptive immune system that develops and acquires memory with the child's growth. From human birth till puberty the immune system undergoes several stages in its development.
A newborn's immune system is in suppression. The phagocytosis system is not developed. Neonatal T-cells greatly differ from adult cells, which is a consequence of antenatal life, when the impact of nonshared antigens is significantly limited by maternal alloantigens.
Therefore, the very early adaptive T-cell immunity is characterized with tolerogenic reactivity, decreased alloantigen recognition and weak responses to nonshared antigens.
Newborns' B-cells greatly differ from an adult's B-cells, too. Neonatal B-cells are known to have decreased TACI, BCMA and BAFF-R expression as well as decreased IgG and IgA production in response to CD4OL and IL-10 (Kaur K, Chowdhury S, Greenspan NS, Schreiber JR. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood. 2007 Oct 15;110(8):2948-54. doi: 10.1182/blood-2007-01-069245. Epub 2007 Jul 18. PMID: 17634409). Together, these peculiarities contribute to depression of humoral immune responses with incomplete switching of the class of immunoglobulins. B-cells of newborns and infants under 2 months demonstrate reduction of somatic hypermutation comparing to adults, which limits affinity maturation of antibodies. Also, stromal cells of bone marrow at early life stages are incapable of supporting long-term survival of plasmablasts and differentiation into plasma cells, so any IgG antibodies produced after immunization quickly decrease, in distinction to children of older age and adults (Pihlgren M, Friedli M, Tougne C, Rochat AF, Lambert PH, Siegrist CA. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol. 2006 Jan 1;176(1):165-72. doi:
10.4049/jimmuno1.176.1.165. PMID: 16365407). As a result, effectiveness of an adaptive immune system as regards early response to T-cell-dependent antigens is much lower in neonatals comparing to children of older age and adults (A.K. Simon, G.A.
Hollander, A.
McMichael. Evolution of the immune system in humans from infancy to old age.
Proc Biol Sci.
2015 Dec 22; 282(1821): 20143085. doi: 10.1098/rspb.2014.3085, PMCID:
PMC4707740, PMID: 26702035).
In infancy the immune system matures gradually. The critically important early protection against many infectious diseases the mother recovered from earlier is provided by passive IgG antibodies transferred from the mother transplacentally and with milk.
4 Date Recue/Date Received 2022-04-06 The next development stage is provided by destruction of maternal antibodies.
The primary immune response to infection penetration develops via synthesis of Class M
immunoglobulins and does not leave immunological memory. Such a type of immune response takes place also in case of vaccination against infectious diseases, and only revaccination forms secondary immune response with production of IgG class antibodies.
With the child grows, his or her contacts with the outer world increase.
Gradually there is switching of immune reactions to formation of IgG class antibodies.
However, the primary immune response to many antigens remains (IgM synthesis). The local immunity system still remains immature. Gradually the average blood concentration of IgG and IgM
increases and reaches the level corresponding to that of adults, however the blood level of IgA still does not reach end values.
The last stage of immune system development is in puberty. At the background of increasing secretion of sex steroids the volume of lymphoid organs decreases.
Secretion of sex hormones causes suppression of the cell immunity chain (Shcheplyagina, L.A., ICruglova, I.V.
Age peculiarities of immunity in children, Russian Medical Journal No. 23 of 11.11.2009, p.
1564).
Thus, developing an agent for utilization for children for effective induction of immune response against the SARS-CoV-2 virus, including developing reactions of humoral and cell immune response against the SARS-CoV-2 virus, is a complex scientific task.
When a child faces SARS-CoV-2, the virus, first of all, affects the mucous membranes of the respiratory tract. It means that interactions between the virus and the immune system first take place primarily on the mucous membranes of the respiratory tract and the oral cavity. Therefore, induction of mucosal immunity is an important factor influencing protective properties of a pharmaceutical agent.
Based on the level of art one can suggest that administration of an adult-intended vaccine to children will reduce its effectiveness owing to immaturity of the child's immune system. However, the conducted research showed that administration of 1/10th of the adult dose of the developed agent to a child induces humoral immune response comparable to the immune response of an adult. In this case this is an unexpected result.
Date Recue/Date Received 2022-04-06 Also, it was demonstrated on young animals that administration of the developed agent induces an increase of the level of IgG antibodies on the mucous membrane of the respiratory tract. Besides, if the intranasal method of agent administration is introduced in the immunization protocol, this leads to secretion of IgG antibodies on the mucous membrane. Thus, as a result of work carried out there were developed agent administration patterns inducing enhanced mucosal response in the respiratory tract.
The given technical result is achieved by what is claimed:
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 site are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID
NO:2, SEQ
Date Recue/Date Received 2022-04-06 ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged I month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID
NO:4, SEQ ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
In particular embodiments:
The agent induces mucosal immune response on mucous membranes of the respiratory tract;
The agent is prepared in a liquid or lyophilized form.
Therein, the liquid form of the agent comprises a buffer, wt. %:
Tris 0.1831 ... 0.3432 sodium chloride 0.3313 ... 0.6212 sucrose 3.7821 ... 7.0915 magnesium chloride hexahydrate 0.0154 ... 0.0289 Date Recue/Date Received 2022-04-06 EDTA 0.0029 ... 0.0054 polysorbate-80 0.0378 ... 0.0709 ethanol 95% 0.0004 ... 0.0007 water rest.
Therein, the reduced lyophilized form of the agent comprises a buffer, wt. %:
Tris 0,0180 ... 0.0338 sodium chloride 0.1044 ... 0.1957 sucrose 5.4688 ... 10.2539 magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 polysorbate-80 0.0037 ... 0.0070 water rest.
In a particular embodiment, a component and/or components of the agent are intended for intranasal and/or intramuscular administration.
In a particular embodiment, the agent is intended for administration with the dose of
The primary immune response to infection penetration develops via synthesis of Class M
immunoglobulins and does not leave immunological memory. Such a type of immune response takes place also in case of vaccination against infectious diseases, and only revaccination forms secondary immune response with production of IgG class antibodies.
With the child grows, his or her contacts with the outer world increase.
Gradually there is switching of immune reactions to formation of IgG class antibodies.
However, the primary immune response to many antigens remains (IgM synthesis). The local immunity system still remains immature. Gradually the average blood concentration of IgG and IgM
increases and reaches the level corresponding to that of adults, however the blood level of IgA still does not reach end values.
The last stage of immune system development is in puberty. At the background of increasing secretion of sex steroids the volume of lymphoid organs decreases.
Secretion of sex hormones causes suppression of the cell immunity chain (Shcheplyagina, L.A., ICruglova, I.V.
Age peculiarities of immunity in children, Russian Medical Journal No. 23 of 11.11.2009, p.
1564).
Thus, developing an agent for utilization for children for effective induction of immune response against the SARS-CoV-2 virus, including developing reactions of humoral and cell immune response against the SARS-CoV-2 virus, is a complex scientific task.
When a child faces SARS-CoV-2, the virus, first of all, affects the mucous membranes of the respiratory tract. It means that interactions between the virus and the immune system first take place primarily on the mucous membranes of the respiratory tract and the oral cavity. Therefore, induction of mucosal immunity is an important factor influencing protective properties of a pharmaceutical agent.
Based on the level of art one can suggest that administration of an adult-intended vaccine to children will reduce its effectiveness owing to immaturity of the child's immune system. However, the conducted research showed that administration of 1/10th of the adult dose of the developed agent to a child induces humoral immune response comparable to the immune response of an adult. In this case this is an unexpected result.
Date Recue/Date Received 2022-04-06 Also, it was demonstrated on young animals that administration of the developed agent induces an increase of the level of IgG antibodies on the mucous membrane of the respiratory tract. Besides, if the intranasal method of agent administration is introduced in the immunization protocol, this leads to secretion of IgG antibodies on the mucous membrane. Thus, as a result of work carried out there were developed agent administration patterns inducing enhanced mucosal response in the respiratory tract.
The given technical result is achieved by what is claimed:
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 site are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID
NO:2, SEQ
Date Recue/Date Received 2022-04-06 ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged I month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID
NO:4, SEQ ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
In particular embodiments:
The agent induces mucosal immune response on mucous membranes of the respiratory tract;
The agent is prepared in a liquid or lyophilized form.
Therein, the liquid form of the agent comprises a buffer, wt. %:
Tris 0.1831 ... 0.3432 sodium chloride 0.3313 ... 0.6212 sucrose 3.7821 ... 7.0915 magnesium chloride hexahydrate 0.0154 ... 0.0289 Date Recue/Date Received 2022-04-06 EDTA 0.0029 ... 0.0054 polysorbate-80 0.0378 ... 0.0709 ethanol 95% 0.0004 ... 0.0007 water rest.
Therein, the reduced lyophilized form of the agent comprises a buffer, wt. %:
Tris 0,0180 ... 0.0338 sodium chloride 0.1044 ... 0.1957 sucrose 5.4688 ... 10.2539 magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 polysorbate-80 0.0037 ... 0.0070 water rest.
In a particular embodiment, a component and/or components of the agent are intended for intranasal and/or intramuscular administration.
In a particular embodiment, the agent is intended for administration with the dose of
5*109- 5*1019 virus particles.
In a particular embodiment, the agent components are intended for sequential administration with an interval of over 1 week or are intended for simultaneous administration.
Therein, the agent components can be in individual packages.
Brief description of figures FIG. 1 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 14 of the study, after immunization of mice with the Date Recue/Date Received 2022-04-06 developed pharmaceutical agent Ad26-CMV-S-CoV2. Dots denote the values for each animal participating in the study. The median value is shown with a black line for each group of data.
Deviations denote 95% confidence interval. The symbol ** denotes a statistically significant difference between values of Days 1 and 14 (p<0.01, Mann-Whitney test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 2 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 14 of the study, after immunization of mice with the developed pharmaceutical agent Ad5-CMV-S-CoV2. Dots denote the values for each animal participating in the study. The median value is shown with a black line for each group of data.
Deviations denote 95% confidence interval. The symbols * (p<0.05) and **
(p<0.01) denote a statistically significant difference between values of Days 1 and 14, Mann-Whitney test.
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 3 illustrates titers of IgG antibodies specific to RBD-domain of SARS-Cov2 virus S protein, before vaccination (Day 1) and on Days 21, 28 and 42 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of lx101 virus particles.
Dots denote the values for each volunteer participating in the study. The mean geometric value of the antibody titer is represented with a black line for each group of data.
Deviations denote 95% confidence interval. The statistically significant difference between values on Days 21, 28 and 42 is shown with a bracket above which the value p, Wilcoxon rank sum test, is shown ( - p<0.0001). UC means uncertain differences between the given data samples. The statistically significant difference between values of Days 21, 28 and 42 comparing to the values before vaccination (Day 1) was determined by Wilcoxon rank sum test (**** -p<0.0001).
Y-axis ¨ titer of antigen-specific IgG antibodies;
X-axis ¨ time, days.
Date Recue/Date Received 2022-04-06 FIG. 4 illustrates titers of IgG antibodies specific to RBD-domain of SARS-Cov2 virus S protein, before vaccination (Day 1) and on Days 21, 28 and 42 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of 2x101 virus particles.
Dots denote the values for each volunteer participating in the study. The mean geometric value of the antibody titer is represented with a black line for each group of data.
Deviations denote 95% confidence interval. The statistically significant difference between values on Days 21, 28 and 42 is shown with a bracket above which the value p, Wilcoxon rank sum test, is shown ( - p<0.0001). UC means uncertain differences between the given data samples. The statistically significant difference between values of Days 21, 28 and 42 comparing to the values before vaccination (Day 1) was determined by Wilcoxon rank sum test (**** -p<0.0001).
Y-axis ¨ titer of antigen-specific IgG antibodies;
X-axis ¨ time, days.
FIG. 5 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 28 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of lx101 virus particles. Dots denote the values for each volunteer participating in the study. The median value is shown with a black line for each group of data. Deviations denote 95% confidence interval. The symbol ****
denotes the statistically significant difference between values of Days 1 and 28 (p<0.0001, according to Wilcoxon rank sum test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 6 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 28 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of 2x1010 virus particles. Dots denote the values for each volunteer participating in the study. The median value is shown with a black line for Date Recue/Date Received 2022-04-06 each group of data. Deviations denote 95% confidence interval. The symbol ****
denotes the statistically significant difference between values of Days 1 and 28 (p<0.0001, according to Wilcoxon rank sum test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days Embodiment of the invention The first stage in the development of an immunobiological agent against the severe acute respiratory syndrome virus SARS-CoV-2 was the selection of a vaccine antigen. As a part of this process, the literature search was performed which demonstrated that the coronavirus S
protein was the most promising antigen for creating a candidate vaccine. This is Type 1 transmembrane glycoprotein responsible for virus particles binding, fusion and entry into the cells. As demonstrated, it is an inducer of neutralizing antibodies (Liang M
et al, SARS
patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity. BiomedEnvironSci. 2005 Dec;18(6):363-74).
To achieve the most effective induction of immune reactions against SARS-CoV-2 S
protein , the authors developed multiple variants of expression cassettes.
The expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The CMV promoter is the promoter of early cytomegalovirus genes that enables constitutive expression in a multitude of cell types.
However, the power of target gene expression managed by the CMV promoter varies depending on the cell type. Moreover, the transgene expression level under control of the CMV promoter was shown to decrease with increase of cell cultivation time due to gene expression suppression, which is related to DNA methylation [Wang W., Jia YL., Li YC., Jing CQ., Guo X., Shang XF., Zhao CP., Wang TY. Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells. //
Scientific Reports - 2017. - Vol. 8. - P. 10416].
The expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The CAG-promoter is the synthetic promoter that includes the early enhancer of the CMV promoter, chicken 13-actin promoter and chimeric intron (chicken p-actin and rabbit fl-globin). It was experimentally shown Date Recue/Date Received 2022-04-06 that the transcription activity of the CAG promoter is higher than that of the CMV
promoter. [Yang C.Q., Li X.Y., Li Q., Fu S.L., Li H., Guo Z.K., Lin J.T., Zhao S.T.
Evaluation of three different promoters driving gene expression in developing chicken embryo by using in vivo electroporation. II Genet. Mol. Res. - 2014. - Vol.
13. - P. 1270-1277].
The expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The EF1-promoter is the promoter of human eukaryotic translation elongation factor 1(3 (EF-1a). The promoter is constitutively active within a wide range of cell types [PMID: 28557288. The EF-la promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells]. The EF-1 a gene encodes the elongation factor-la, which is one of the most widely spread proteins in eukaryotic cells and is expressed in all types of mammalian cells.
This EF-Ia promoter is often active in the cells in which virus promoters are incapable of expressing controlled genes and in cells in which virus promoters are gradually suppressed.
The expression cassette SEQ ID NO:4 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
For effective delivery of SARS-CoV-2 coronavirus S protein gene into the human organism a vector system based on adenoviridae was selected. Adenovirus vectors have a whole range of advantages: they are incapable of proliferating in human cells, they penetrate both in proliferating and non-proliferating cells, they are capable of inducing cell and humoral immune response, they ensure a high level of target antigen expression.
The authors developed variants of the agent comprising two components as well as variants comprising one component based on adenoviridae of different serotypes. Thus, the immune response to the adenovirus vector part, which can arise after administration of the first component of the agent or single-component agent is not boostered further on and does not influence generation of antigen-specific immune responses against the vaccine antigen in case of utilization of the two-component agent or in case of the need in repeated administration of the single-component agent as in the latter case an agent based on another adenovirus can be administered.
Besides, the developed agents widen the range of agents for induction of immune response against the SARS-CoV-2 coronavirus, which will enable overcoming of Date Recue/Date Received 2022-04-06 difficulties related to the problem of presence of pre-immunity to some serotypes of adenoviridae in a part of population.
Thus, as a result of work carried out the following technical solutions were developed.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 site are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:31 and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in Date Recue/Date Received 2022-04-06 which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID
NO:4, SEQ ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
In particular embodiments:
The agent induces mucosal immune response on mucous membranes of the respiratory tract;
The agent is prepared in a liquid or lyophilized form.
Therein, the liquid form of the agent comprises a buffer, wt. %:
Tris 0.1831 ... 0.3432 sodium chloride 0.3313 ... 0.6212 sucrose 3.7821 ... 7.0915 magnesium chloride hexahydrate 0.0154 ... 0.0289 EDTA 0.0029 ... 0.0054 polysorbate-80 0.0378 0.0709 Date Recue/Date Received 2022-04-06 ethanol 95% 0.0004 ... 0.0007 water rest.
Therein, the reduced lyophilized form of the agent comprises a buffer, wt. %:
Tris 0.0180 ... 0.0338 sodium chloride 0.1044 ... 0.1957 sucrose 5.4688 ... 10.2539 magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 polysorbate-80 0.0037 ... 0.0070 water rest.
In a particular embodiment, a component and/or components of the agent are intended for intranasal and/or intramuscular administration.
In a particular embodiment, the agent is intended for administration with the dose of 5* 109- 5*101 virus particles.
In a particular embodiment, the agent components are intended for sequential administration with an interval of over 1 week or are intended for simultaneous administration.
Therein, the agent components can be in individual packages.
Moreover, the authors developed buffer variants that enable storing both in a frozen form at temperature below -18 C and in the form of a lyophilisate at temperature from +2 C to +8 C.
Also, they developed utilization of the agent for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older by administering it in the organism in an effective quantity.
Date Recue/Date Received 2022-04-06 The developed agent was shown to induce mucosal immune response on mucous membranes of the respiratory tract.
Moreover, the agent, also consisting of one component, can be used once.
Revaccination can be performed with any of the claimed agents irrespective of the agent used for vaccination.
Embodiment of the invention is supported with the following examples.
Example 1 Obtaining of an expression vector comprising the genome of recombinant human adenovirus serotype 26.
At the first stage of the work the design of the plasmid construct pAd26-Ends comprising two sites homologous to the genome of human adenovirus serotype 26 (two homology arms) and the gene of resistance to ampicillin. One homology arm is the beginning of the genome of human adenovirus serotype 26 (from the left inverted terminal repeat to El site) and the sequence of the virus genome comprising pIX
protein. The second homology arm comprises the nucleotide sequence after ORF3 E4 site to the genome end. The pAd26-Ends construct was synthesized by CJSC "Evrogen"
(Moscow).
Human adenovirus serotype 26 DNA isolated from virions was mixed with pAd26-Ends. As a result of homologous recombination between pAd26-Ends and virus DNA
the pAd26-d1E1 plasmid was obtained that comprised the genome of human adenovirus serotype 26 with deleted El site.
Then, in the obtained pAd26-d1E1 plasmid with the use of standard cloning methods the sequence comprising open reading frame 6 (ORF6-Ad26) was replaced with the similar sequence from the genome of human adenovirus serotype 5 so that human adenovirus serotype 26 would be capable of effective propagation in HEK293 cell culture.
As a result, the pAd26-d1E 1 -ORF6-Ad5 plasmid was obtained.
Then, with the use of standard genetic engineering methods in the constructed plasmid pAd26-dlEl-ORF6-Ad5 E3 site of the adenovirus genome (approximately b.p. between genes pVIII and U-exon) was deleted to increase vector packing capacity. As a result, the recombinant vector pAd26-only-null based on the genome of human Date Recue/Date Received 2022-04-06 adenovirus serotype 26 with open reading frame ORF6 of human adenovirus serotype 5 and with deletion of El and E3 sites was obtained.
Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
On the basis of the plasmid construct pAd26-Ends, using the genetic engineering method, constructs pArms-26-CMV-S-CoV2, pArms-26-CAG-S-CoV2, pArms-26-EF1-S-CoV2 were obtained that comprised expression cassettes SEQ ID NO:1, SEQ ID
NO:2 or SEQ ID NO:3, respectively, as well as homology arms of adenovirus serotype 26 genome.
Afterwards, the constructs pArms-26-CMV-S-CoV2, pArms-26-CAG-S-CoV2, pArms-26-EF l-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pAd26-only-null. As a result of homologous recombination there were obtained the pAd26-only-CMV-S-CoV2, pAd26-only-CAG-S-CoV2, pAd26-only-EFI-S-CoV2 plasmids comprising the genome of recombinant human adenovirus serotype 26 with the open reading frame ORF6 of human adenovirus serotype 5 and with deletion of El and E3 sites, with the expression cassette SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the fourth stage, the pAd26-only-CMV-S-CoV2, pAd26-only-CAG-S-CoV2, pAd26-only-EF1-S-CoV2 plasmids were hydrolyzed with specific restriction endonucleases to delete the vector part. The obtained DNA preparations were used to transfect HEK293 culture cells.
Thus, the expression vector was obtained that comprised the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 region was replaced with ORF6-Ad5 with the integrated expression cassette selected from SEQ ID NO:I, SEQ ID NO:2, SEQ ID NO:3.
ii Date Recue/Date Received 2022-04-06 Example 2 Obtaining of an agent in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the integrated expression cassette selected from SEQ ID NO:!, SEQ ID NO:2, SEQ ID NO:3.
At the given stage of work the expression vectors obtained in example 1 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5:
1. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CMV
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad26-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CMV
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad26-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CAG
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad26-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CAG
promoter, the Date Recue/Date Received 2022-04-06 gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad26-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad26-EFI-S-CoV2) in a buffer for the liquid form of the agent.
In a particular embodiment, the agent components are intended for sequential administration with an interval of over 1 week or are intended for simultaneous administration.
Therein, the agent components can be in individual packages.
Brief description of figures FIG. 1 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 14 of the study, after immunization of mice with the Date Recue/Date Received 2022-04-06 developed pharmaceutical agent Ad26-CMV-S-CoV2. Dots denote the values for each animal participating in the study. The median value is shown with a black line for each group of data.
Deviations denote 95% confidence interval. The symbol ** denotes a statistically significant difference between values of Days 1 and 14 (p<0.01, Mann-Whitney test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 2 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 14 of the study, after immunization of mice with the developed pharmaceutical agent Ad5-CMV-S-CoV2. Dots denote the values for each animal participating in the study. The median value is shown with a black line for each group of data.
Deviations denote 95% confidence interval. The symbols * (p<0.05) and **
(p<0.01) denote a statistically significant difference between values of Days 1 and 14, Mann-Whitney test.
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 3 illustrates titers of IgG antibodies specific to RBD-domain of SARS-Cov2 virus S protein, before vaccination (Day 1) and on Days 21, 28 and 42 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of lx101 virus particles.
Dots denote the values for each volunteer participating in the study. The mean geometric value of the antibody titer is represented with a black line for each group of data.
Deviations denote 95% confidence interval. The statistically significant difference between values on Days 21, 28 and 42 is shown with a bracket above which the value p, Wilcoxon rank sum test, is shown (
Y-axis ¨ titer of antigen-specific IgG antibodies;
X-axis ¨ time, days.
Date Recue/Date Received 2022-04-06 FIG. 4 illustrates titers of IgG antibodies specific to RBD-domain of SARS-Cov2 virus S protein, before vaccination (Day 1) and on Days 21, 28 and 42 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of 2x101 virus particles.
Dots denote the values for each volunteer participating in the study. The mean geometric value of the antibody titer is represented with a black line for each group of data.
Deviations denote 95% confidence interval. The statistically significant difference between values on Days 21, 28 and 42 is shown with a bracket above which the value p, Wilcoxon rank sum test, is shown (
Y-axis ¨ titer of antigen-specific IgG antibodies;
X-axis ¨ time, days.
FIG. 5 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 28 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of lx101 virus particles. Dots denote the values for each volunteer participating in the study. The median value is shown with a black line for each group of data. Deviations denote 95% confidence interval. The symbol ****
denotes the statistically significant difference between values of Days 1 and 28 (p<0.0001, according to Wilcoxon rank sum test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days FIG. 6 illustrates the percentage of proliferating CD4+ (A) and CD8+ (B) T
lymphocytes before immunization (Day 1) and on Day 28 of the study, after immunization of volunteers with the developed pharmaceutical agent with the dose of 2x1010 virus particles. Dots denote the values for each volunteer participating in the study. The median value is shown with a black line for Date Recue/Date Received 2022-04-06 each group of data. Deviations denote 95% confidence interval. The symbol ****
denotes the statistically significant difference between values of Days 1 and 28 (p<0.0001, according to Wilcoxon rank sum test).
Y-axis ¨ number of proliferating cells, %
X-axis ¨ time, days Embodiment of the invention The first stage in the development of an immunobiological agent against the severe acute respiratory syndrome virus SARS-CoV-2 was the selection of a vaccine antigen. As a part of this process, the literature search was performed which demonstrated that the coronavirus S
protein was the most promising antigen for creating a candidate vaccine. This is Type 1 transmembrane glycoprotein responsible for virus particles binding, fusion and entry into the cells. As demonstrated, it is an inducer of neutralizing antibodies (Liang M
et al, SARS
patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity. BiomedEnvironSci. 2005 Dec;18(6):363-74).
To achieve the most effective induction of immune reactions against SARS-CoV-2 S
protein , the authors developed multiple variants of expression cassettes.
The expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The CMV promoter is the promoter of early cytomegalovirus genes that enables constitutive expression in a multitude of cell types.
However, the power of target gene expression managed by the CMV promoter varies depending on the cell type. Moreover, the transgene expression level under control of the CMV promoter was shown to decrease with increase of cell cultivation time due to gene expression suppression, which is related to DNA methylation [Wang W., Jia YL., Li YC., Jing CQ., Guo X., Shang XF., Zhao CP., Wang TY. Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells. //
Scientific Reports - 2017. - Vol. 8. - P. 10416].
The expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The CAG-promoter is the synthetic promoter that includes the early enhancer of the CMV promoter, chicken 13-actin promoter and chimeric intron (chicken p-actin and rabbit fl-globin). It was experimentally shown Date Recue/Date Received 2022-04-06 that the transcription activity of the CAG promoter is higher than that of the CMV
promoter. [Yang C.Q., Li X.Y., Li Q., Fu S.L., Li H., Guo Z.K., Lin J.T., Zhao S.T.
Evaluation of three different promoters driving gene expression in developing chicken embryo by using in vivo electroporation. II Genet. Mol. Res. - 2014. - Vol.
13. - P. 1270-1277].
The expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal. The EF1-promoter is the promoter of human eukaryotic translation elongation factor 1(3 (EF-1a). The promoter is constitutively active within a wide range of cell types [PMID: 28557288. The EF-la promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells]. The EF-1 a gene encodes the elongation factor-la, which is one of the most widely spread proteins in eukaryotic cells and is expressed in all types of mammalian cells.
This EF-Ia promoter is often active in the cells in which virus promoters are incapable of expressing controlled genes and in cells in which virus promoters are gradually suppressed.
The expression cassette SEQ ID NO:4 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
For effective delivery of SARS-CoV-2 coronavirus S protein gene into the human organism a vector system based on adenoviridae was selected. Adenovirus vectors have a whole range of advantages: they are incapable of proliferating in human cells, they penetrate both in proliferating and non-proliferating cells, they are capable of inducing cell and humoral immune response, they ensure a high level of target antigen expression.
The authors developed variants of the agent comprising two components as well as variants comprising one component based on adenoviridae of different serotypes. Thus, the immune response to the adenovirus vector part, which can arise after administration of the first component of the agent or single-component agent is not boostered further on and does not influence generation of antigen-specific immune responses against the vaccine antigen in case of utilization of the two-component agent or in case of the need in repeated administration of the single-component agent as in the latter case an agent based on another adenovirus can be administered.
Besides, the developed agents widen the range of agents for induction of immune response against the SARS-CoV-2 coronavirus, which will enable overcoming of Date Recue/Date Received 2022-04-06 difficulties related to the problem of presence of pre-immunity to some serotypes of adenoviridae in a part of population.
Thus, as a result of work carried out the following technical solutions were developed.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 site are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:31 and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in Date Recue/Date Received 2022-04-06 which El and E3 sites are deleted, while ORF6-Ad26 site is replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, and component 2 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID
NO:4, SEQ ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID
NO:2, SEQ
ID NO:3 for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
In particular embodiments:
The agent induces mucosal immune response on mucous membranes of the respiratory tract;
The agent is prepared in a liquid or lyophilized form.
Therein, the liquid form of the agent comprises a buffer, wt. %:
Tris 0.1831 ... 0.3432 sodium chloride 0.3313 ... 0.6212 sucrose 3.7821 ... 7.0915 magnesium chloride hexahydrate 0.0154 ... 0.0289 EDTA 0.0029 ... 0.0054 polysorbate-80 0.0378 0.0709 Date Recue/Date Received 2022-04-06 ethanol 95% 0.0004 ... 0.0007 water rest.
Therein, the reduced lyophilized form of the agent comprises a buffer, wt. %:
Tris 0.0180 ... 0.0338 sodium chloride 0.1044 ... 0.1957 sucrose 5.4688 ... 10.2539 magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 polysorbate-80 0.0037 ... 0.0070 water rest.
In a particular embodiment, a component and/or components of the agent are intended for intranasal and/or intramuscular administration.
In a particular embodiment, the agent is intended for administration with the dose of 5* 109- 5*101 virus particles.
In a particular embodiment, the agent components are intended for sequential administration with an interval of over 1 week or are intended for simultaneous administration.
Therein, the agent components can be in individual packages.
Moreover, the authors developed buffer variants that enable storing both in a frozen form at temperature below -18 C and in the form of a lyophilisate at temperature from +2 C to +8 C.
Also, they developed utilization of the agent for induction of specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older by administering it in the organism in an effective quantity.
Date Recue/Date Received 2022-04-06 The developed agent was shown to induce mucosal immune response on mucous membranes of the respiratory tract.
Moreover, the agent, also consisting of one component, can be used once.
Revaccination can be performed with any of the claimed agents irrespective of the agent used for vaccination.
Embodiment of the invention is supported with the following examples.
Example 1 Obtaining of an expression vector comprising the genome of recombinant human adenovirus serotype 26.
At the first stage of the work the design of the plasmid construct pAd26-Ends comprising two sites homologous to the genome of human adenovirus serotype 26 (two homology arms) and the gene of resistance to ampicillin. One homology arm is the beginning of the genome of human adenovirus serotype 26 (from the left inverted terminal repeat to El site) and the sequence of the virus genome comprising pIX
protein. The second homology arm comprises the nucleotide sequence after ORF3 E4 site to the genome end. The pAd26-Ends construct was synthesized by CJSC "Evrogen"
(Moscow).
Human adenovirus serotype 26 DNA isolated from virions was mixed with pAd26-Ends. As a result of homologous recombination between pAd26-Ends and virus DNA
the pAd26-d1E1 plasmid was obtained that comprised the genome of human adenovirus serotype 26 with deleted El site.
Then, in the obtained pAd26-d1E1 plasmid with the use of standard cloning methods the sequence comprising open reading frame 6 (ORF6-Ad26) was replaced with the similar sequence from the genome of human adenovirus serotype 5 so that human adenovirus serotype 26 would be capable of effective propagation in HEK293 cell culture.
As a result, the pAd26-d1E 1 -ORF6-Ad5 plasmid was obtained.
Then, with the use of standard genetic engineering methods in the constructed plasmid pAd26-dlEl-ORF6-Ad5 E3 site of the adenovirus genome (approximately b.p. between genes pVIII and U-exon) was deleted to increase vector packing capacity. As a result, the recombinant vector pAd26-only-null based on the genome of human Date Recue/Date Received 2022-04-06 adenovirus serotype 26 with open reading frame ORF6 of human adenovirus serotype 5 and with deletion of El and E3 sites was obtained.
Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
On the basis of the plasmid construct pAd26-Ends, using the genetic engineering method, constructs pArms-26-CMV-S-CoV2, pArms-26-CAG-S-CoV2, pArms-26-EF1-S-CoV2 were obtained that comprised expression cassettes SEQ ID NO:1, SEQ ID
NO:2 or SEQ ID NO:3, respectively, as well as homology arms of adenovirus serotype 26 genome.
Afterwards, the constructs pArms-26-CMV-S-CoV2, pArms-26-CAG-S-CoV2, pArms-26-EF l-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pAd26-only-null. As a result of homologous recombination there were obtained the pAd26-only-CMV-S-CoV2, pAd26-only-CAG-S-CoV2, pAd26-only-EFI-S-CoV2 plasmids comprising the genome of recombinant human adenovirus serotype 26 with the open reading frame ORF6 of human adenovirus serotype 5 and with deletion of El and E3 sites, with the expression cassette SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the fourth stage, the pAd26-only-CMV-S-CoV2, pAd26-only-CAG-S-CoV2, pAd26-only-EF1-S-CoV2 plasmids were hydrolyzed with specific restriction endonucleases to delete the vector part. The obtained DNA preparations were used to transfect HEK293 culture cells.
Thus, the expression vector was obtained that comprised the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 region was replaced with ORF6-Ad5 with the integrated expression cassette selected from SEQ ID NO:I, SEQ ID NO:2, SEQ ID NO:3.
ii Date Recue/Date Received 2022-04-06 Example 2 Obtaining of an agent in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the integrated expression cassette selected from SEQ ID NO:!, SEQ ID NO:2, SEQ ID NO:3.
At the given stage of work the expression vectors obtained in example 1 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5:
1. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CMV
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad26-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CMV
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad26-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CAG
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad26-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the CAG
promoter, the Date Recue/Date Received 2022-04-06 gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad26-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad26-EFI-S-CoV2) in a buffer for the liquid form of the agent.
6. The immunobiological agent based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with the expression cassette comprising the EF I
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad26-EF 1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 1 in variant 1 and in variant 2 of the developed agent.
Example 3 Obtaining of an expression vector comprising the genome of recombinant simian adenovirus serotype 25.
At the first stage of work there was developed the design of the pSim25-Ends plasmid construct comprising two regions homologous to the genome of simian adenovirus serotype 25 (two homology arms). One homology arm is the beginning of the genome of simian adenovirus serotype 25 (from the left inverted terminal repeat to El site) and the sequence from the end of El site to pIVa2 protein. The second homology arm comprises the sequence of the end of adenovirus genome, including the right inverted terminal repeat. The pSim25-Ends construct was synthesized by CJSC "Evrogen"
(Moscow).
Simian adenovirus serotype 25 DNA isolated from virions was mixed with pSim25-Ends. As a result of homologous recombination between pSim25-Ends and virus DNA the pSim25-d1E1 plasmid was obtained that comprised the genome of simian adenovirus serotype 25 with deleted El site.
Date Recue/Date Received 2022-04-06 Then, with the use of standard genetic engineering methods in the constructed pSim25-d1E1 plasmid E3 site of the adenovirus genome (3921 b.p. from the beginning of gene 12,5K to gene 14,7K) was deleted to increase the vector packing capacity.
As a result the pSim25-null plasmid construct was obtained that encoded the full genome of simian adenovirus serotype 25 with deletion of El and E3 sites.
Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:4 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
Then, using the genetic engineering method, on the basis of the plasmid construct pSim25-Ends, constructs pArms-Sim25-CMV-S-CoV2, pArms-Sim25-CAG-S-CoV2, pArms-Sim25-EF1-S-CoV2 were obtained that comprised expression cassettes SEQ
ID
NO:4, SEQ ID NO:2 or SEQ ID NO:3, respectively, as well as homology arms of simian adenovirus serotype 25. Afterwards, the constructs pArms-Sim25-CMV-S-CoV2, pArms-Sim25-CAG-S-CoV2, pArms-Sim25-EF1-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pSim25-null. As a result of homologous recombination recombinant plasmid vectors pSim25-CMV-S-CoV2, pSim25-CAG-S-CoV2, pSim25-EF1-S-CoV2 were obtained that comprised the full genome of simian adenovirus serotype 25 with deletion of El and E3 sites and the expression cassette SEQ ID NO:4, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the third stage the pSim25-CMV-S-CoV2, pSim25-CAG-S-CoV2, pSim25-EF1-S-CoV2 plasmids were hydrolyzed with the specific restriction endonuclease to delete the vector part. The obtained DNA preparations were used to transfect HEK293 culture cells.
The obtained material was used to accumulate preparatory quantities of recombinant adenoviridae.
Date Recue/Date Received 2022-04-06 As a result, there were obtained recombinant human adenoviridae serotype 25 comprising the gene of SARS-CoV-2 virus S protein: simAd25-CMV-S-CoV2 (comprising the expression cassette SEQ ID NO:4), simAd25-CAG-S-CoV2 (comprising the expression cassette SEQ ID NO:2), simAd25-EF I-S-CoV2 (comprising the expression cassette SEQ ID NO:3).
Thus, the expression vector was obtained that comprised the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3.
Example 4 Obtaining of an agent in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID
NO:3.
At the given stage of work the expression vectors obtained in example 3 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites:
I. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (simAd25-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (Ad26-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette Date Recue/Date Received 2022-04-06 ' comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (simAd25-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (simAd25-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the EF I promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (simAd25-EF1-S-CoV2) in a buffer for the liquid form of the agent.
6. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (simAd25-EF1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 2 in variant 1 of the developed agent and component 1 in variant 3 of the developed agent.
Example 5 Obtaining of an expression vector comprising the genome of recombinant human adenovirus serotype 5.
At the first stage of work there was developed the design of the pAd5-Ends plasmid construct comprising two regions homologous to the genome of human adenovirus serotype 5 (two homology arms). One homology arm is the beginning of the genome of human adenovirus serotype 5 (from the left inverted terminal repeat to El site) and the sequence of the virus genome comprising pIX protein. The second homology arm comprises the nucleotide sequence after ORF3 E4 site to the genome end. The pAd5-Ends construct was synthesized by CJSC "EVrogen" (Moscow).
Date Recue/Date Received 2022-04-06 Human adenovirus serotype 5 DNA isolated from virions was mixed with pAd5-Ends. As a result of homologous recombination between pAd5-Ends and virus DNA
the pAd5-dIE1 plasmid was obtained that comprised the genome of human adenovirus serotype 5 with deleted El site.
Then, with the use of standard genetic engineering methods in the constructed pAd5-d1E1 plasmid E3 site of the adenovirus genome (2685 b.p. from the end of gene 12,5K to the beginning of sequence U-exon) was deleted to increase the vector packing capacity.
As a result, there was obtained the recombinant plasmid vector pAd5-too-null based on the genome of human adenovirus serotype 5 with deletion of El and E3 sites of the genome. Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
Then, using the genetic engineering method, on the basis of the plasmid construct pAd5-Ends, constructs pArms-Ad5-CMV-S-CoV2, pArms-Ad5-CAG-S-CoV2, pArms-Ad5-EFI-S-CoV2 were obtained that comprised expression cassettes SEQ ID NO:1, SEQ
ID NO:2 or SEQ ID NO:3, respectively, as well as homology arms of the genome of adenovirus serotype 5.
Afterwards, the constructs pArms-Ad5-CMV-S-CoV2, pArms-Ad5-CAG-S-CoV2, pArms-Ad5-EF1-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pAd5-too-null. As a result of homologous recombination, there were obtained pAd5-too-CMV-S-CoV2, pAd5-too-GAC-S-CoV2, pAd5-too-EF1-S-CoV2 plasmids comprising the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites and expression cassettes SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the fourth stage the pAd5-too-CMV-S-CoV2, pAd5-too-GAC-S-CoV2, pAd5-too-EF1-S-CoV2 plasmids were hydrolyzed with the specific restriction endonuclease to Date Recue/Date Received 2022-04-06 delete the vector part. The obtained DNA preparation was used to transfect culture cells. The obtained material was used to accumulate preparatory quantities of the recombinant adenovirus.
As a result, there were obtained recombinant human adenoviridae serotype 5 comprising the gene of S SARS-CoV-2 virus S protein: Ad5-CMV-S-CoV2 (comprising the expression cassette SEQ ID NO:1), Ad5-CAG-S-CoV2 (comprising the expression cassette SEQ ID NO:2), Ad5-EF1-S-CoV2 (comprising the expression cassette SEQ
ID
NO:3).
Thus, the expression vector was obtained that comprised the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3.
Example 6 Obtaining of an agent in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3.
At the given stage of work the expression vectors obtained in example 5 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites:
1. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad5-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and Date Recue/Date Received 2022-04-06 polyadenylation signal, SEQ ID NO:1 (Ad5-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad5-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad5-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad5-EF1-S-CoV2) in a buffer for the liquid form of the agent.
6. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad5-EF1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 2 in variant 1 and in variant 3 of the developed agent.
Example 7 Obtaining of a buffer.
Each component of the developed agent is an agent based on the recombinant adenovirus with an expression cassette in a buffer.
Date Recue/Date Received 2022-04-06 The authors of the invention developed a buffer composition that ensured stability of recombinant adenovirus particles. The given solution comprises:
1. Tris(hydroxymethyl)aminomethane (Tris), which is required to maintain pH
of the solution.
2. Sodium chloride, which is added to obtain the required ionic strength and osmolarity.
3. Sucrose, which is used as a cryoprotector.
4. Magnesium chloride hexahydrate, which is required as a source of divalent cations.
5. EDTA, which is used as a free-radical oxidation inhibitor.
6. Polysorbate-80, which is used as a surfactant.
promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad26-EF 1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 1 in variant 1 and in variant 2 of the developed agent.
Example 3 Obtaining of an expression vector comprising the genome of recombinant simian adenovirus serotype 25.
At the first stage of work there was developed the design of the pSim25-Ends plasmid construct comprising two regions homologous to the genome of simian adenovirus serotype 25 (two homology arms). One homology arm is the beginning of the genome of simian adenovirus serotype 25 (from the left inverted terminal repeat to El site) and the sequence from the end of El site to pIVa2 protein. The second homology arm comprises the sequence of the end of adenovirus genome, including the right inverted terminal repeat. The pSim25-Ends construct was synthesized by CJSC "Evrogen"
(Moscow).
Simian adenovirus serotype 25 DNA isolated from virions was mixed with pSim25-Ends. As a result of homologous recombination between pSim25-Ends and virus DNA the pSim25-d1E1 plasmid was obtained that comprised the genome of simian adenovirus serotype 25 with deleted El site.
Date Recue/Date Received 2022-04-06 Then, with the use of standard genetic engineering methods in the constructed pSim25-d1E1 plasmid E3 site of the adenovirus genome (3921 b.p. from the beginning of gene 12,5K to gene 14,7K) was deleted to increase the vector packing capacity.
As a result the pSim25-null plasmid construct was obtained that encoded the full genome of simian adenovirus serotype 25 with deletion of El and E3 sites.
Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:4 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
Then, using the genetic engineering method, on the basis of the plasmid construct pSim25-Ends, constructs pArms-Sim25-CMV-S-CoV2, pArms-Sim25-CAG-S-CoV2, pArms-Sim25-EF1-S-CoV2 were obtained that comprised expression cassettes SEQ
ID
NO:4, SEQ ID NO:2 or SEQ ID NO:3, respectively, as well as homology arms of simian adenovirus serotype 25. Afterwards, the constructs pArms-Sim25-CMV-S-CoV2, pArms-Sim25-CAG-S-CoV2, pArms-Sim25-EF1-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pSim25-null. As a result of homologous recombination recombinant plasmid vectors pSim25-CMV-S-CoV2, pSim25-CAG-S-CoV2, pSim25-EF1-S-CoV2 were obtained that comprised the full genome of simian adenovirus serotype 25 with deletion of El and E3 sites and the expression cassette SEQ ID NO:4, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the third stage the pSim25-CMV-S-CoV2, pSim25-CAG-S-CoV2, pSim25-EF1-S-CoV2 plasmids were hydrolyzed with the specific restriction endonuclease to delete the vector part. The obtained DNA preparations were used to transfect HEK293 culture cells.
The obtained material was used to accumulate preparatory quantities of recombinant adenoviridae.
Date Recue/Date Received 2022-04-06 As a result, there were obtained recombinant human adenoviridae serotype 25 comprising the gene of SARS-CoV-2 virus S protein: simAd25-CMV-S-CoV2 (comprising the expression cassette SEQ ID NO:4), simAd25-CAG-S-CoV2 (comprising the expression cassette SEQ ID NO:2), simAd25-EF I-S-CoV2 (comprising the expression cassette SEQ ID NO:3).
Thus, the expression vector was obtained that comprised the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3.
Example 4 Obtaining of an agent in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID
NO:3.
At the given stage of work the expression vectors obtained in example 3 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites:
I. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (simAd25-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (Ad26-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette Date Recue/Date Received 2022-04-06 ' comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:4 (simAd25-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (simAd25-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the EF I promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (simAd25-EF1-S-CoV2) in a buffer for the liquid form of the agent.
6. The immunobiological agent based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (simAd25-EF1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 2 in variant 1 of the developed agent and component 1 in variant 3 of the developed agent.
Example 5 Obtaining of an expression vector comprising the genome of recombinant human adenovirus serotype 5.
At the first stage of work there was developed the design of the pAd5-Ends plasmid construct comprising two regions homologous to the genome of human adenovirus serotype 5 (two homology arms). One homology arm is the beginning of the genome of human adenovirus serotype 5 (from the left inverted terminal repeat to El site) and the sequence of the virus genome comprising pIX protein. The second homology arm comprises the nucleotide sequence after ORF3 E4 site to the genome end. The pAd5-Ends construct was synthesized by CJSC "EVrogen" (Moscow).
Date Recue/Date Received 2022-04-06 Human adenovirus serotype 5 DNA isolated from virions was mixed with pAd5-Ends. As a result of homologous recombination between pAd5-Ends and virus DNA
the pAd5-dIE1 plasmid was obtained that comprised the genome of human adenovirus serotype 5 with deleted El site.
Then, with the use of standard genetic engineering methods in the constructed pAd5-d1E1 plasmid E3 site of the adenovirus genome (2685 b.p. from the end of gene 12,5K to the beginning of sequence U-exon) was deleted to increase the vector packing capacity.
As a result, there was obtained the recombinant plasmid vector pAd5-too-null based on the genome of human adenovirus serotype 5 with deletion of El and E3 sites of the genome. Moreover, the authors developed several expression cassette designs:
- the expression cassette SEQ ID NO:1 consists of the CMV promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:2 consists of the CAG promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal;
- the expression cassette SEQ ID NO:3 consists of the EF1 promoter, gene of SARS-CoV-2 virus S protein and polyadenylation signal.
Then, using the genetic engineering method, on the basis of the plasmid construct pAd5-Ends, constructs pArms-Ad5-CMV-S-CoV2, pArms-Ad5-CAG-S-CoV2, pArms-Ad5-EFI-S-CoV2 were obtained that comprised expression cassettes SEQ ID NO:1, SEQ
ID NO:2 or SEQ ID NO:3, respectively, as well as homology arms of the genome of adenovirus serotype 5.
Afterwards, the constructs pArms-Ad5-CMV-S-CoV2, pArms-Ad5-CAG-S-CoV2, pArms-Ad5-EF1-S-CoV2 were linearized by the unique site of hydrolysis between homology arms, each plasmid was mixed with the recombinant vector pAd5-too-null. As a result of homologous recombination, there were obtained pAd5-too-CMV-S-CoV2, pAd5-too-GAC-S-CoV2, pAd5-too-EF1-S-CoV2 plasmids comprising the genome of recombinant human adenovirus serotype 5 with deletion of El and E3 sites and expression cassettes SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, respectively.
At the fourth stage the pAd5-too-CMV-S-CoV2, pAd5-too-GAC-S-CoV2, pAd5-too-EF1-S-CoV2 plasmids were hydrolyzed with the specific restriction endonuclease to Date Recue/Date Received 2022-04-06 delete the vector part. The obtained DNA preparation was used to transfect culture cells. The obtained material was used to accumulate preparatory quantities of the recombinant adenovirus.
As a result, there were obtained recombinant human adenoviridae serotype 5 comprising the gene of S SARS-CoV-2 virus S protein: Ad5-CMV-S-CoV2 (comprising the expression cassette SEQ ID NO:1), Ad5-CAG-S-CoV2 (comprising the expression cassette SEQ ID NO:2), Ad5-EF1-S-CoV2 (comprising the expression cassette SEQ
ID
NO:3).
Thus, the expression vector was obtained that comprised the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3.
Example 6 Obtaining of an agent in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3.
At the given stage of work the expression vectors obtained in example 5 were purified with the method of anion-exchange and exclusion chromatography. The ready suspension comprised adenovirus particles in a buffer for the liquid form of the agent or in a buffer for lyophilized form of the agent.
Thus, there were obtained the following immunobiological agents based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites:
1. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:1 (Ad5-CMV-S-CoV2) in a buffer for the liquid form of the agent.
2. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and Date Recue/Date Received 2022-04-06 polyadenylation signal, SEQ ID NO:1 (Ad5-CMV-S-CoV2) in a buffer for the lyophilized form of the agent.
3. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad5-CAG-S-CoV2) in a buffer for the liquid form of the agent.
4. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the CAG promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:2 (Ad5-CAG-S-CoV2) in a buffer for the lyophilized form of the agent.
5. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad5-EF1-S-CoV2) in a buffer for the liquid form of the agent.
6. The immunobiological agent based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with the expression cassette comprising the EF1 promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, SEQ ID NO:3 (Ad5-EF1-S-CoV2) in a buffer for the lyophilized form of the agent.
Each of the given immunobiological agents is component 2 in variant 1 and in variant 3 of the developed agent.
Example 7 Obtaining of a buffer.
Each component of the developed agent is an agent based on the recombinant adenovirus with an expression cassette in a buffer.
Date Recue/Date Received 2022-04-06 The authors of the invention developed a buffer composition that ensured stability of recombinant adenovirus particles. The given solution comprises:
1. Tris(hydroxymethyl)aminomethane (Tris), which is required to maintain pH
of the solution.
2. Sodium chloride, which is added to obtain the required ionic strength and osmolarity.
3. Sucrose, which is used as a cryoprotector.
4. Magnesium chloride hexahydrate, which is required as a source of divalent cations.
5. EDTA, which is used as a free-radical oxidation inhibitor.
6. Polysorbate-80, which is used as a surfactant.
7. Ethanol 95%, which is used as a free-radical oxidation inhibitor.
8. Water, which is used as a solvent.
The authors of the invention developed 2 buffer variants: for the liquid form of the agent and for the lyophilized form of the pharmaceutical agent.
To determine the concentration of substances included in the buffer for the liquid form of the agent, several variants of experimental groups were obtained (Table 1). One of the components of the agent was added to each of the obtained buffers:
1. The immunobiological agent based on the recombinant human adenovirus serotype 26 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, l*levirus particles.
2. The immunobiological agent based on the recombinant human adenovirus serotype 5 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*101 virus particles.
3. The immunobiological agent based on the recombinant simian adenovirus serotype 25 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1* 1010 virus particles.
Date Recue/Date Received 2022-04-06 Thus, stability of each of the serotypes of adenoviridae included in the agent was tested. The obtained agents were stored at the temperature of -18 C and -70 C
during 3 months, then defrosted and the change of the titer of the recombinant adenoviridae was analyzed.
TABLE 1 - Composition Of Experimental Buffers For The Liquid Form Of The Agent.
Buffer composition Group Magnesium Sodium Ethanol No. Tris Sucrose chloride EDTA Polysorbate-chloride 95% Water (mg) (mg) hexahydrate (mg) 80 (mg) (mg) (mg) (mg) under 1 0.968 2.19 25 0.102 0.019 0.25 0.0025 0.5 ml under 2 1.815 2.19 25 0.102 0.019 0.25 0.0025 0.5 ml under 3 1.21 1.752 25 0.102 0.019 0.25 0.0025 0.5 ml under 4 1.21 3.285 25 0.102 0.019 0.25 0.0025 0.5 ml under 1.21 2.19 20 0.102 0.019 0.25 0.0025 0.5 ml under 6 1.21 2.19 37.5 0.102 0.019 0.25 0.0025 0.5 ml under 7 1.21 2.19 25 0.0816 0.019 0.25 0.0025 0.5 ml Date Recue/Date Received 2022-04-06 under 8 1.21 2.19 25 0.153 0.019 0.25 0.0025 0.5 ml under
The authors of the invention developed 2 buffer variants: for the liquid form of the agent and for the lyophilized form of the pharmaceutical agent.
To determine the concentration of substances included in the buffer for the liquid form of the agent, several variants of experimental groups were obtained (Table 1). One of the components of the agent was added to each of the obtained buffers:
1. The immunobiological agent based on the recombinant human adenovirus serotype 26 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, l*levirus particles.
2. The immunobiological agent based on the recombinant human adenovirus serotype 5 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*101 virus particles.
3. The immunobiological agent based on the recombinant simian adenovirus serotype 25 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1* 1010 virus particles.
Date Recue/Date Received 2022-04-06 Thus, stability of each of the serotypes of adenoviridae included in the agent was tested. The obtained agents were stored at the temperature of -18 C and -70 C
during 3 months, then defrosted and the change of the titer of the recombinant adenoviridae was analyzed.
TABLE 1 - Composition Of Experimental Buffers For The Liquid Form Of The Agent.
Buffer composition Group Magnesium Sodium Ethanol No. Tris Sucrose chloride EDTA Polysorbate-chloride 95% Water (mg) (mg) hexahydrate (mg) 80 (mg) (mg) (mg) (mg) under 1 0.968 2.19 25 0.102 0.019 0.25 0.0025 0.5 ml under 2 1.815 2.19 25 0.102 0.019 0.25 0.0025 0.5 ml under 3 1.21 1.752 25 0.102 0.019 0.25 0.0025 0.5 ml under 4 1.21 3.285 25 0.102 0.019 0.25 0.0025 0.5 ml under 1.21 2.19 20 0.102 0.019 0.25 0.0025 0.5 ml under 6 1.21 2.19 37.5 0.102 0.019 0.25 0.0025 0.5 ml under 7 1.21 2.19 25 0.0816 0.019 0.25 0.0025 0.5 ml Date Recue/Date Received 2022-04-06 under 8 1.21 2.19 25 0.153 0.019 0.25 0.0025 0.5 ml under
9 1.21 2.19 25 0.102 0.0152 0.25 0.0025 0.5 ml under 1.21 2.19 25 0.102 0.0285 0.25 0.0025 0.5 ml under 11 1.21 2.19 25 0.102 0.019 0.2 0.0025 0.5 ml under 12 1.21 2.19 25 0.102 0.019 0.375 0.0025 0.5 ml under 13 1.21 2.19 25 0.102 0.019 0.25 0.002 0.5 ml under 14 1.21 2.19 25 0.102 0.019 0.25 0.00375 0.5 ml under 1.21 2.19 25 0.102 0.019 0.25 0.0025 0.5 ml The results of the carried out experiment demonstrated that the titer of recombinant adenoviridae after their storage in the buffer for the liquid form of the agent at temperatures -18 C and -70 C during 3 months did not change.
Thus, the developed buffer for the liquid form of the agent ensures stability of all components of the developed agent in the following range of active ingredients (wt. %):
Tris: 0.1831 wt. % 0.3432 wt. %;
Sodium chloride: 0.3313 wt. % ... 0.6212 wt. %;
Sucrose: 3.7821 wt. % 7.0915 wt. %;
Date Recue/Date Received 2022-04-06 Magnesium chloride hexahydrate: 0.0154 wt. % ... 0.0289 wt. %;
EDTA: 0.0029 wt. % ... 0.0054 wt. %;
Polysorbate-80: 0.0378 wt. % ... 0.0709 wt. %;
Ethanol 95%: 0.0004 wt. % ... 0.0007 wt. A);
Solvent: the rest.
To determine the concentration of substances included in the buffer for the lyophilized form of the agent, several variants of experimental groups were obtained (table 2). One of the components of the agent was added to each of the obtained buffers:
I. The immunobiological agent based on the recombinant human adenovirus serotype 26 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*101 virus particles.
2. The immunobiological agent based on the recombinant human adenovirus serotype 5 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*1010 virus particles.
3. The immunobiological agent based on the recombinant simian adenovirus serotype 25 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*1010 virus particles.
Thus, stability of each of the serotypes of adenoviridae included in the agent was tested. The obtained agents were stored at the temperature of +2 and +8 C
during 3 months, then defrosted and the change of the titer of the recombinant adenoviridae was analyzed.
Date Recue/Date Received 2022-04-06 Table 2 - Composition of Experimental Buffers.
Buffer composition Group Sodium Magnesium No. Tris Sucrose EDTA Polysorbate-chloride chloride Water (mg) (mg) (mg) 80 (mg) (mg) hexahydrate (mg) under 1 0.1936 1.403 73.5 0.0204 0.0038 0.05 1 ml under 2 0.363 1.403 73.5 0.0204 0.0038 0.05 1 ml under 3 0.242 1.1224 73.5 0.0204 0.0038 0.05 1 ml under 4 0.242 2.1045 73.5 0.0204 0.0038 0.05 1 ml under 0.242 1.403 58.8 0.0204 0.0038 0.05 1 ml under 6 0.242 1.403 110.25 0.0204 0.0038 0.05 1 ml under 7 0.242 1.403 73.5 0.01632 0.0038 0.05 1 ml under 8 0.242 1.403 73.5 0.0306 0.0038 0.05 1 ml under 9 0.242 1.403 73.5 0.0204 0.00304 0.05 1 ml
Thus, the developed buffer for the liquid form of the agent ensures stability of all components of the developed agent in the following range of active ingredients (wt. %):
Tris: 0.1831 wt. % 0.3432 wt. %;
Sodium chloride: 0.3313 wt. % ... 0.6212 wt. %;
Sucrose: 3.7821 wt. % 7.0915 wt. %;
Date Recue/Date Received 2022-04-06 Magnesium chloride hexahydrate: 0.0154 wt. % ... 0.0289 wt. %;
EDTA: 0.0029 wt. % ... 0.0054 wt. %;
Polysorbate-80: 0.0378 wt. % ... 0.0709 wt. %;
Ethanol 95%: 0.0004 wt. % ... 0.0007 wt. A);
Solvent: the rest.
To determine the concentration of substances included in the buffer for the lyophilized form of the agent, several variants of experimental groups were obtained (table 2). One of the components of the agent was added to each of the obtained buffers:
I. The immunobiological agent based on the recombinant human adenovirus serotype 26 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*101 virus particles.
2. The immunobiological agent based on the recombinant human adenovirus serotype 5 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*1010 virus particles.
3. The immunobiological agent based on the recombinant simian adenovirus serotype 25 with the expression cassette comprising the CMV promoter, the gene of SARS-CoV-2 virus S protein and polyadenylation signal, 1*1010 virus particles.
Thus, stability of each of the serotypes of adenoviridae included in the agent was tested. The obtained agents were stored at the temperature of +2 and +8 C
during 3 months, then defrosted and the change of the titer of the recombinant adenoviridae was analyzed.
Date Recue/Date Received 2022-04-06 Table 2 - Composition of Experimental Buffers.
Buffer composition Group Sodium Magnesium No. Tris Sucrose EDTA Polysorbate-chloride chloride Water (mg) (mg) (mg) 80 (mg) (mg) hexahydrate (mg) under 1 0.1936 1.403 73.5 0.0204 0.0038 0.05 1 ml under 2 0.363 1.403 73.5 0.0204 0.0038 0.05 1 ml under 3 0.242 1.1224 73.5 0.0204 0.0038 0.05 1 ml under 4 0.242 2.1045 73.5 0.0204 0.0038 0.05 1 ml under 0.242 1.403 58.8 0.0204 0.0038 0.05 1 ml under 6 0.242 1.403 110.25 0.0204 0.0038 0.05 1 ml under 7 0.242 1.403 73.5 0.01632 0.0038 0.05 1 ml under 8 0.242 1.403 73.5 0.0306 0.0038 0.05 1 ml under 9 0.242 1.403 73.5 0.0204 0.00304 0.05 1 ml
10 0.242 1.403 73.5 0.0204 0.0057 0.05 under Date Recue/Date Received 2022-04-06 1 ml under
11 0.242 1.403 73.5 0.0204 0.0038 0.04 1 ml under
12 0.242 1.403 73.5 0.0204 0.0038 0.075 1 ml under
13 0.242 1.403 73.5 0.0204 0.0038 0.05 1 ml The results of the carried out experiment demonstrated that the titer of recombinant adenoviridae after their storage in the buffer for the lyophilized form of the agent at temperature +2 C and +8 C during 3 months did not change.
Thus, the developed buffer for the lyophilized form of the agent ensures stability of all components of the developed agent in the following range of active ingredients:
Tris: 0.0180 wt. % ... 0.0338 wt. %;
Sodium chloride: 0.1044 wt. % ... 0.1957 wt. %;
Sucrose: 5.4688 wt. % ... 10.2539 wt. %;
Magnesium chloride hexahydrate: 0.0015 wt. % ... 0.0028 wt. %;
EDTA: 0.0003 wt. % 0.0005 wt. %;
Polysorbate-80: 0.0037 wt. % ... 0.0070 wt. %;
Solvent: the rest.
Example 8 Assessing of the ability of the developed agent to induce mucosal immune response upon intramuscular administration.
For this study young mice of BALM line (aged 21-28 days) were used. The animals were distributed by groups of 10 and the following agents were administered to them:
Date Recue/Date Received 2022-04-06 =
1) Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 5x109 v.p./100 ul; in 21 days Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 5x109 v.p./100 ul.
2) Ad5-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109 v.p./100u1.
3) simAd25-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days simAd25-CMV-S-CoV2, i/m, dose 5x109 v.p./100u1 4) Ad26-null, i/m, dose 5x109v.p./100u1; in 21 days Ad26-null, i/m, dose 5x109 v.p./100u1 5) Ad5-null, i/m, dose 5x109v.p./100u1; in 21 days Ad5-null, i/m, dose 5x109 v.p./100u1 6) simAd25-null, i/m, dose 5x109v.p./100u1; in 21 days simAd25-null, i/m, dose 5x109 v.p./100u1 7) Ad26-CMV-S-CoV2, intranasally (i/n), dose 5x109 v.p./100u1; in 21 days Ad26-CMV-S-CoV2 i/n, dose 5x109 v.p./100u1.
8) Ad5-CMV-S-CoV2, i/n, dose 5x109 v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109v.p./100u1.
9) Ad26-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad26-CMV-S-CoV2 i/n, dose 5x109v.p./100u1.
10) Ad5-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109v.p./100u1.
11)Buffer After 14 days after the latest immunization the titer of IgG and IgA
antibodies was determined by the ELISA method in bronchoalveolar lavages (BAL) of experimental animals.
To do that:
1) The antigen (recombinant RBD) was adsorbed on the wells of a 96-well plate for ELISA during 16 hours at +4 C.
Date Recue/Date Received 2022-04-06 2) The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3) BAL samples were diluted 25 times and then by the method of 2-fold dilutions.
4) 50 ul of each diluted serum sample were added to the plate wells.
5) Then, the samples were incubated for an hour at 37 C.
6) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7) The secondary antibodies to mouse irrununoglobulins conjugated with horseradish peroxidase were added.
8) Then, the samples were incubated for an hour at 37 C.
9) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10) Then tetrarnethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 3.
Table 3. Mean Geometrical Value Of The Titer Of Igg And Iga Antibodies To SARS-Cov-2 Virus S Protein In BAL Lavages Of Experimental Animals Titer of IgG Titer of IgA
Group name antibodies antibodies 1 Ad26-CMV-S-CoV2 ihn; Ad26-CMV-S-CoV2 162 3 i/m Date Recue/Date Received 2022-04-06 Titer of IgG Titer of IgA
Group name antibodies antibodies 2 Ad5-CMV-S-CoV2 i/m, Ad5-CMV-S-CoV2 325 4 3 simAd25-CMV-S-CoV2 iim, simAd25-CMV-S- 214 3 CoV2 i/m 4 Ad26-CMV-S-CoV2 i/n; Ad26-CMV-S-CoV2 123 76 i/n Ad5-CMV-S-CoV2 i/n, Ad5-CMV-S-CoV2 264 81 6 Ad26-CMV-S-CoV2 i/m; Ad26-CMV-S-CoV2 373 283 i/n 7 Ad5-CMV-S-CoV2 i/m, Ad5-CMV-S-CoV2 348 303 8 Ad26-null i/m; Ad26-null i/m; 0 0 9 Ad5-null i/m; Ad5-null i/m; 0 0 simAd25-null i/m; simAd25-null i/m; 0 0 11 Ad26-null i/n; Ad26-null i/n; 0 0 12 Ad5-null i/n; Ad5-null i/n; 0 0 13 Buffer 0 0 According to the given results, all variants of the developed agent cause an increase of the titer of IgG antibodies on the surface of mucous membrane of the respiratory tract. Expression of IgA antibodies depends on the agent administration method. Maximum titers of IgA
antibodies are induced when the animals are immunized sequentially:
intramuscularly and then intranasally.
Thus, as a result of the work carried out an immunobiological agent was developed that is capable of inducing mucosa] immune response against SARS-CoV-2 virus on the mucous Date Recue/Date Received 2022-04-06 membrane of the respiratory tract in children as well as a pattern of administration of this agent leading to potentiation of the mucosal immune response.
Example 9 Assessing of the ability of the developed agent to induce immune response in mammals of different age.
For this study young mice of BALB/c of different age were used. The animals were distributed into groups of 5:
1) Mice aged 15-18 days 2) Mice aged 28 -35 days 3) Mice aged 50-60 days All the animals were immunized once with the developed immunobiological agent based on human adenovirus serotype 5 (Ad5-CMV-S-CoV2) with the dose of 108 v.p./50 ul. On Day 21 after immunization the titer of IgG antibodies in the animal blood serum was measured.
To do that:
1) The antigen (recombinant RBD) was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2) The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3) The serum samples were diluted 50 times and then by the method of 2-fold dilutions.
4) 50 ul of each diluted serum sample were added to the plate wells.
5) Then, the samples were incubated for an hour at 37 C.
6) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7) The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8) Then, the samples were incubated for an hour at 37 C.
Date Recue/Date Received 2022-04-06 9) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10) Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 4.
Table 4. The Mean Geometrical Value Of The Titer Of Igg Antibodies To SARS-Cov-2 Virus S Protein In The Blood Serum Of Experimental Animals Depending On Their Age.
No. Age of animals Titer of IgG antibodies 1 15-18 days 6400 2 28-35 days 5572 3 50-60 days 4222 Thus, as it is shown from the provided data, the developed immunobiological agent induces development of humoral immune response both in adult and young animals of different age. This makes it possible to suggest that the agent will be effective in utilization for people of different age categories.
Example 10 Study of immunogenicity of the developed agent on young mice for assessment of cell immune response after single vaccination.
Young BAL13/c mice (aged 21-28 days) were used for the immunogenicity study.
The animals were distributed into groups of 5 to whom the following agents were administered once:
Date Recue/Date Received 2022-04-06 1. Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 1010 vp/100 ul;
2. Ad5-CMV-S-CoV2, intramuscularly (i/m), dose 1010 vp/100 ul Cell immunity level was determined by assessing the quantity of proliferating CD4+ and CD8+ lymphocytes isolated from mouse spleen in the culture in vitro after repeated cell restimulation with recombinant S protein of SARS-CoV-2. Before immunization as well as after 14 days animals' spleens were harvested from which mononuclear cells were isolated by centrifugation in the ficoll solution density gradient (1.09 g/mL; PanEco).
Then, the isolated cells were colored with the fluorescent dye CFSE (Invivogen, USA) and seeded on wells of a 96-well plate (2* 105 cells/well). The repeated stimulation of lymphocytes was carried out in in vitro conditions by adding coronavirus S protein to the culture medium (final protein concentration 1 ug/m1). Intact cells to which the antigen was not added were used as the negative control.
To determine % of proliferating cells they were stained with antibodies to marker molecules of T lymphocytes CD3, CD4, CD8 (BDBioscienses, USA). Proliferating (with a lower quantity of cell colorant CFSE) CD4+ and CD8+ T lymphocytes were determined in the cell mixture with the use of the flow cytofluorometer BD FACS AriaIII (BD
Biosciences, USA). The resultant percentage of proliferating cells in each sample was determined by deducing the result obtained during analysis of intact cells from the result obtained during analysis of cells restimulated with coronavirus S protein antigen.
The results (with conducted statistical processing) of determination of the percentage of proliferating CD4+ and CD8+ T lymphocytes on Day 1 (before immunization) and on Day 14 of the study are given in Fig. 1 (Ad26-CMV-S-CoV2) and Fig. 2 (Ad5-CMV-S-CoV2).
The obtained data showed that single immunization of mice with the developed agent makes it possible to reliably increase the percentage of proliferating CD4+
and CD8+ T
lymphocytes after antigen restimulation on Day 14 after immunization.
Thus, one can conclude that single immunization of mice with the developed immunobiological agent is capable of causing formation of high-level post-vaccination cell immunity.
Date Recue/Date Received 2022-04-06 Example 11 Study of immunogenicity of the developed agent on young mice with different administration methods.
Young BALB/c mice (aged 21-28 days) were used for the immunogenicity study.
The animals were distributed by groups of 5 and the following agents were administered to them:
3. Ad26-CMV-S-CoV2,intramuscularly (i/m),dose 109vp/100 ul 4. Ad26-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 5. Ad26-EF1-S-CoV2,intramuscularly,dose 109vp/100 ul 6. Ad5-CMV-S-CoV2,intramuscularly,dose 109vp/100 ul 7. Ad5-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 8. Ad5-EF 1 -S-CoV2,intramuscularly,dose 109vp/100 ul 9. simAd25-CMV-S-CoV2,intramuscularly,dose 109vp/100 ul 10. simAd25-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 11. simAd25-EF1-S-CoV2,intramuscularly,dose 109vp/100 ul 12. Ad26-CMV-S-CoV2,intranasally (i/n),dose 109vp/100 ul 13. Ad26-CAG-S-CoV2,intranasally (i/n),dose 109vp/100 ul
Thus, the developed buffer for the lyophilized form of the agent ensures stability of all components of the developed agent in the following range of active ingredients:
Tris: 0.0180 wt. % ... 0.0338 wt. %;
Sodium chloride: 0.1044 wt. % ... 0.1957 wt. %;
Sucrose: 5.4688 wt. % ... 10.2539 wt. %;
Magnesium chloride hexahydrate: 0.0015 wt. % ... 0.0028 wt. %;
EDTA: 0.0003 wt. % 0.0005 wt. %;
Polysorbate-80: 0.0037 wt. % ... 0.0070 wt. %;
Solvent: the rest.
Example 8 Assessing of the ability of the developed agent to induce mucosal immune response upon intramuscular administration.
For this study young mice of BALM line (aged 21-28 days) were used. The animals were distributed by groups of 10 and the following agents were administered to them:
Date Recue/Date Received 2022-04-06 =
1) Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 5x109 v.p./100 ul; in 21 days Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 5x109 v.p./100 ul.
2) Ad5-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109 v.p./100u1.
3) simAd25-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days simAd25-CMV-S-CoV2, i/m, dose 5x109 v.p./100u1 4) Ad26-null, i/m, dose 5x109v.p./100u1; in 21 days Ad26-null, i/m, dose 5x109 v.p./100u1 5) Ad5-null, i/m, dose 5x109v.p./100u1; in 21 days Ad5-null, i/m, dose 5x109 v.p./100u1 6) simAd25-null, i/m, dose 5x109v.p./100u1; in 21 days simAd25-null, i/m, dose 5x109 v.p./100u1 7) Ad26-CMV-S-CoV2, intranasally (i/n), dose 5x109 v.p./100u1; in 21 days Ad26-CMV-S-CoV2 i/n, dose 5x109 v.p./100u1.
8) Ad5-CMV-S-CoV2, i/n, dose 5x109 v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109v.p./100u1.
9) Ad26-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad26-CMV-S-CoV2 i/n, dose 5x109v.p./100u1.
10) Ad5-CMV-S-CoV2, i/m, dose 5x109v.p./100u1; in 21 days Ad5-CMV-S-CoV2, i/n, dose 5x109v.p./100u1.
11)Buffer After 14 days after the latest immunization the titer of IgG and IgA
antibodies was determined by the ELISA method in bronchoalveolar lavages (BAL) of experimental animals.
To do that:
1) The antigen (recombinant RBD) was adsorbed on the wells of a 96-well plate for ELISA during 16 hours at +4 C.
Date Recue/Date Received 2022-04-06 2) The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3) BAL samples were diluted 25 times and then by the method of 2-fold dilutions.
4) 50 ul of each diluted serum sample were added to the plate wells.
5) Then, the samples were incubated for an hour at 37 C.
6) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7) The secondary antibodies to mouse irrununoglobulins conjugated with horseradish peroxidase were added.
8) Then, the samples were incubated for an hour at 37 C.
9) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10) Then tetrarnethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 3.
Table 3. Mean Geometrical Value Of The Titer Of Igg And Iga Antibodies To SARS-Cov-2 Virus S Protein In BAL Lavages Of Experimental Animals Titer of IgG Titer of IgA
Group name antibodies antibodies 1 Ad26-CMV-S-CoV2 ihn; Ad26-CMV-S-CoV2 162 3 i/m Date Recue/Date Received 2022-04-06 Titer of IgG Titer of IgA
Group name antibodies antibodies 2 Ad5-CMV-S-CoV2 i/m, Ad5-CMV-S-CoV2 325 4 3 simAd25-CMV-S-CoV2 iim, simAd25-CMV-S- 214 3 CoV2 i/m 4 Ad26-CMV-S-CoV2 i/n; Ad26-CMV-S-CoV2 123 76 i/n Ad5-CMV-S-CoV2 i/n, Ad5-CMV-S-CoV2 264 81 6 Ad26-CMV-S-CoV2 i/m; Ad26-CMV-S-CoV2 373 283 i/n 7 Ad5-CMV-S-CoV2 i/m, Ad5-CMV-S-CoV2 348 303 8 Ad26-null i/m; Ad26-null i/m; 0 0 9 Ad5-null i/m; Ad5-null i/m; 0 0 simAd25-null i/m; simAd25-null i/m; 0 0 11 Ad26-null i/n; Ad26-null i/n; 0 0 12 Ad5-null i/n; Ad5-null i/n; 0 0 13 Buffer 0 0 According to the given results, all variants of the developed agent cause an increase of the titer of IgG antibodies on the surface of mucous membrane of the respiratory tract. Expression of IgA antibodies depends on the agent administration method. Maximum titers of IgA
antibodies are induced when the animals are immunized sequentially:
intramuscularly and then intranasally.
Thus, as a result of the work carried out an immunobiological agent was developed that is capable of inducing mucosa] immune response against SARS-CoV-2 virus on the mucous Date Recue/Date Received 2022-04-06 membrane of the respiratory tract in children as well as a pattern of administration of this agent leading to potentiation of the mucosal immune response.
Example 9 Assessing of the ability of the developed agent to induce immune response in mammals of different age.
For this study young mice of BALB/c of different age were used. The animals were distributed into groups of 5:
1) Mice aged 15-18 days 2) Mice aged 28 -35 days 3) Mice aged 50-60 days All the animals were immunized once with the developed immunobiological agent based on human adenovirus serotype 5 (Ad5-CMV-S-CoV2) with the dose of 108 v.p./50 ul. On Day 21 after immunization the titer of IgG antibodies in the animal blood serum was measured.
To do that:
1) The antigen (recombinant RBD) was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2) The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3) The serum samples were diluted 50 times and then by the method of 2-fold dilutions.
4) 50 ul of each diluted serum sample were added to the plate wells.
5) Then, the samples were incubated for an hour at 37 C.
6) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7) The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8) Then, the samples were incubated for an hour at 37 C.
Date Recue/Date Received 2022-04-06 9) The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10) Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 4.
Table 4. The Mean Geometrical Value Of The Titer Of Igg Antibodies To SARS-Cov-2 Virus S Protein In The Blood Serum Of Experimental Animals Depending On Their Age.
No. Age of animals Titer of IgG antibodies 1 15-18 days 6400 2 28-35 days 5572 3 50-60 days 4222 Thus, as it is shown from the provided data, the developed immunobiological agent induces development of humoral immune response both in adult and young animals of different age. This makes it possible to suggest that the agent will be effective in utilization for people of different age categories.
Example 10 Study of immunogenicity of the developed agent on young mice for assessment of cell immune response after single vaccination.
Young BAL13/c mice (aged 21-28 days) were used for the immunogenicity study.
The animals were distributed into groups of 5 to whom the following agents were administered once:
Date Recue/Date Received 2022-04-06 1. Ad26-CMV-S-CoV2, intramuscularly (i/m), dose 1010 vp/100 ul;
2. Ad5-CMV-S-CoV2, intramuscularly (i/m), dose 1010 vp/100 ul Cell immunity level was determined by assessing the quantity of proliferating CD4+ and CD8+ lymphocytes isolated from mouse spleen in the culture in vitro after repeated cell restimulation with recombinant S protein of SARS-CoV-2. Before immunization as well as after 14 days animals' spleens were harvested from which mononuclear cells were isolated by centrifugation in the ficoll solution density gradient (1.09 g/mL; PanEco).
Then, the isolated cells were colored with the fluorescent dye CFSE (Invivogen, USA) and seeded on wells of a 96-well plate (2* 105 cells/well). The repeated stimulation of lymphocytes was carried out in in vitro conditions by adding coronavirus S protein to the culture medium (final protein concentration 1 ug/m1). Intact cells to which the antigen was not added were used as the negative control.
To determine % of proliferating cells they were stained with antibodies to marker molecules of T lymphocytes CD3, CD4, CD8 (BDBioscienses, USA). Proliferating (with a lower quantity of cell colorant CFSE) CD4+ and CD8+ T lymphocytes were determined in the cell mixture with the use of the flow cytofluorometer BD FACS AriaIII (BD
Biosciences, USA). The resultant percentage of proliferating cells in each sample was determined by deducing the result obtained during analysis of intact cells from the result obtained during analysis of cells restimulated with coronavirus S protein antigen.
The results (with conducted statistical processing) of determination of the percentage of proliferating CD4+ and CD8+ T lymphocytes on Day 1 (before immunization) and on Day 14 of the study are given in Fig. 1 (Ad26-CMV-S-CoV2) and Fig. 2 (Ad5-CMV-S-CoV2).
The obtained data showed that single immunization of mice with the developed agent makes it possible to reliably increase the percentage of proliferating CD4+
and CD8+ T
lymphocytes after antigen restimulation on Day 14 after immunization.
Thus, one can conclude that single immunization of mice with the developed immunobiological agent is capable of causing formation of high-level post-vaccination cell immunity.
Date Recue/Date Received 2022-04-06 Example 11 Study of immunogenicity of the developed agent on young mice with different administration methods.
Young BALB/c mice (aged 21-28 days) were used for the immunogenicity study.
The animals were distributed by groups of 5 and the following agents were administered to them:
3. Ad26-CMV-S-CoV2,intramuscularly (i/m),dose 109vp/100 ul 4. Ad26-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 5. Ad26-EF1-S-CoV2,intramuscularly,dose 109vp/100 ul 6. Ad5-CMV-S-CoV2,intramuscularly,dose 109vp/100 ul 7. Ad5-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 8. Ad5-EF 1 -S-CoV2,intramuscularly,dose 109vp/100 ul 9. simAd25-CMV-S-CoV2,intramuscularly,dose 109vp/100 ul 10. simAd25-CAG-S-CoV2,intramuscularly,dose 109vp/100 ul 11. simAd25-EF1-S-CoV2,intramuscularly,dose 109vp/100 ul 12. Ad26-CMV-S-CoV2,intranasally (i/n),dose 109vp/100 ul 13. Ad26-CAG-S-CoV2,intranasally (i/n),dose 109vp/100 ul
14. Ad26-EF1-S-CoV2,intranasally (i/n),dose 109vp/I00 ul
15. Ad5-CMV-S-CoV2,intranasally (i/n),dose 109vp/100 ul
16. Ad5-CAG-S-CoV2,intranasally (i/n),dose 109vp/100 ul
17. Ad5-EF1-S-CoV2,intranasally (i/n),dose 109vp/100 ul
18. simAd25-CMV-S-CoV2,intranasally (i/n),dose 109vp/100 ul
19. simAd25-CAG-S-CoV2,intranasally (i/n),dose 109vp/100 ul
20. simAd25-EF1-S-CoV2,intranasally (i/n),dose 109vp/100 ul Date Recue/Date Received 2022-04-06 In 21 days the animals blood was drawn, blood serum was isolated and the titer of IgG antibodies to S protein of SARS-CoV-2 coronavirus was determined by the ELISA
method. To do that:
I. The antigen was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted by the method of 2-fold dilutions. In total, 12 dilutions of each sample were prepared.
4, 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of IgG antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 5.
Date Recue/Date Received 2022-04-06 Table 5¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG antibodies 1 Ad26-CMV-S-CoV2, i/m 696 2 Ad26-CAG-S-CoV2, i/m 528 3 Ad26-EF1-S-CoV2 i/m 459 4 Ad5-CMV-S-CoV2, i/m 9701 Ad5-CAG-S-CoV2, i/m 11143 6 Ad5-EF1-S-CoV2, i/m 14703 7 simAd25-CMV-S-CoV2, i/m 3676 8 simAd25-CAG-S-CoV2, i/m 5572 9 simAd25-EF1-S-CoV2, i/m 3676 Ad26-CMV-S-CoV2, i/n 230 11 Ad26-CAG-S-CoV2, i/n 200 12 Ad26-EF1-S-CoV2, i/n 174 Date Recue/Date Received 2022-04-06 Group of animals Titer of IgG antibodies 13 Ad5-CMV-S-CoV2, 606 14 Ad5-CAG-S-CoV2, i/n 459 15 Ad5-EF I -S-CoV2, i/n 459 16 simAd25-CMV-S-CoV2, i/n 459 17 simAd25-CAG-S-CoV2, i/n 400 18 simAd25-EF1-S-CoV2, i/n 303 Based on the given data, single immunization with the developed agent induces humoral immune response to SARS-CoV-2 glycoprotein.
Example 12 Study of immunogenicity of the developed agent upon administration to young animals in different doses.
The aim of the given study was assessment of humoral immune response to S
protein of SARS-CoV-2 with administration of the developed agent in different doses to young animals.
Young mice of C57/B16 line (3-4 weeks) were used to study immunogenicity of the developed agent. The animals were distributed by groups of 5 to whom the following agents were administered intramuscularly, twice, with an interval of 28 days:
1) Ad5-CMV-S-CoV2, 5*109vp/100 ul, 2) Ad5-CMV-S-CoV2, 10'0vp/100 ul, 3) Ad5-CMV-S-CoV2, 5*101 vp/100 ul.
Date Recue/Date Received 2022-04-06 In 21 days the animals' blood was drawn, blood serum was isolated and the titer of IgG antibodies to S protein of SARS-CoV-2 coronavirus was determined by the ELISA
method. To do that:
1. The antigen was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted 100 times and then by the method of 2-fold dilutions. In total, 12 dilutions of each sample were prepared.
4. 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 6.
Date Recue/Date Received 2022-04-06 Table 6¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG antibodies 1 Ad5-CMV-S-CoV2, 5*109vp/100 ul, 22286 2 Ad5-CMV-S-CoV2, 101 vp/100 ul, 44572 3 Ad5-CMV-S-CoV2, 5*101 vp/100 ul. 117627 Based on the given data, the developed agent demonstrates immunogenicity within the whole range of selected doses.
Example 13 Study of immunogenicity of the developed agent on young mice with different administration protocols.
Young mice of C57/B16 line (3-4 weeks) were used to study immunogenicity of the developed agent. The animals were distributed by groups of 5 and the following agents were administered to them:
1) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
2) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2i/m, 109vp/100 ul;
3) Ad26-CMV-S-CoV2, i/n, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2i/m, 109vp/100 ul;
4) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks simAd5-CMV-S-CoV2i/m, 109vp/100 ul;
Date Recue/Date Received 2022-04-06 5) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2 i/m, l0svp/100 ul;
6) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
7) Ad5-CMV-S-CoV2, i/n, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
8) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul;in 3 weekssimAd5-CMV-S-CoV2i/m, 109vp/100 ul;
9) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weekssimAd5-CMV-S-CoV2i/m, 109vp/100 ul;
10) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks Ad5-CMV-S-CoV2 i/m, 109vp/100 ul;
11) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks Ad26-CMV-S-CoV2, i/m, 109vp/100 ul.
In 21 days the animals' blood was drawn, blood serum was isolated and the titer of IgG antibodies to S protein of SARS-CoV-2 coronavirus was determined by the ELISA
method. To do that:
1. The antigen was adsorbed on the wells of a 96-well plate for ELISA during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted by the method of 2-fold dilutions.
In total, 12 dilutions of each sample were prepared.
4. 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
Date Recue/Date Received 2022-04-06 7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound.
11. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 7.
Table 7 ¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG
antibodies 1 Ad26-CMV-S-CoV2 i/m, Ad26-CMV-S-CoV2 i/m 11143 2 Ad26-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 29407 3 Ad26-CMV-S-CoV2, i/n, Ad5-CMV-S-CoV2 22286 4 Ad26-CMV-S-CoV2, simAd5-CMV-S-CoV2 i/m, 14703 Ad5-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 16890 6 Ad5-CMV-S-CoV2, i/m, Ad26-CMV-S-CoV2 i/m, 33779 7 Ad5-CMV-S-CoV2, i/n, Ad26-CMV-S-CoV2 i/m, 25600 Date Recue/Date Received 2022-04-06 Group of animals Titer of IgG
antibodies 8 Ad5-CMV-S-CoV2, i/m, sirnAd5-CMV-S-CoV2 i/m, 14703 9 simAd5-CMV-S-CoV2, i/m, simAd5-CMV-S-CoV2 i/m, 12800 simAd5-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 16890 11 simAd5-CMV-S-CoV2, Ad26-CMV-S-CoV2, i/m 14703 The obtained results demonstrate that the developed agent provides for development of humoral immune response against SARS-CoV-2 in young animals with different administration protocols.
Example 14 Study of utilization of the developed agent for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 for children.
100 volunteers aged 12-17 years participated in the given study. The suggested immunization protocol included sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent according to variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2). One volunteer discontinued participation before administration of component 1 because of newly diagnosed hypertension, correspondingly, 99 volunteers started the therapy under study. Component 2 was not administered to: 1 person ¨ because of non-attendance, 1 person - because of an adverse event (leukopenia), 1 person - because of an intestinal infection of unknown etiology (of enteroviral type), 1 person - because of hospitalization with a purulent furunculus in 5 days after administration of the component, 1 person - because of hospitalization (an intestinal infection) and 1 person - because of COVID, 2 people - refused to participate. Correspondingly, both vaccine components were received by 91 volunteers.
205 AEs that developed in 73 volunteers (73.0%) after vaccine administration were recorded. Table 8 includes the number (share) of volunteers with presence of AE in each group by the system organ class (SOC) and preferred term (PT) according to the MedDRA dictionary, as well as by connection with the preparation under study and severity degree.
The intergroup comparison of the frequency of AE development was conducted by means of x2-test and, if Date Recue/Date Received 2022-04-06 required, Fisher exact test, if the expected frequency in any of the cells was below 5. The analysis did not reveal statistically significant differences by the frequency of individual AE
between the groups.
Table 8. Adverse Events Recorded During The Analyzed Period By System Organ Classes, Preferred Terms And Groups (FAS-Population) Group 1 Group 2 Total (dose 1/10) .. (dose 1/5) N = 100 P-Description N=50 N=50 value N % N % N %
Any PT 37 74.0 36 72.0 73 73.0 0.822 General disorders and reactions at the place of administration (78 AE
episodes) Pain at place of injection 15 30.0 11 22.0 26 26.0 0.362 Tenderness (1) 7 14.0 7 14.0 14 14.0 1.000 Hyperthermia 5 10.0 3 6.0 8 8.0 0.715 Influenza like illness 3 6.0 5 10.0 8 8.0 0.715 Erythema at place of injection 4 8.0 0 0.0 4 4.0 0.117 Itching at place of injection 1 2.0 0 0.0 1 1.0 1.000 Local temperature increase at place of 1 2.0 0 0.0 1 1.0 1.000 administration Shivering 1 2.0 0 0.0 1 1.0 1.000 Edema at place of injection 1 2.0 0 0.0 1 1.0 1.000 Pyrexia 0 0.0 1 2.0 1 1.0 1.000 Date Recue/Date Received 2022-04-06 Total in the organ system 29 58.0 23 46.0 52 52.0 0.230 Laboratory and instrumental data (76 AE episodes) Reduction of neutrophil count 17 34.0 18 36.0 35 35.0 0.834 Positive result of urine analysis for 8 16.0 5 10.0 13 13.0 0.372 erythrocytes Increase of blood bilirubin level 3 6.0 2 4.0 5 5.0 1.000 Presence of protein in urine 1 2.0 2 4.0 3 3.0 1.000 Reduction of hemoglobin level 1 2,0 2 4.0 3 3.0 1.000 Presence of leukocytes in urine 1 2.0 1 2.0 2 2.0 1.000 Increase of blood alkaline phosphatase 1 2.0 1 2.0 2 2.0 1.000 Reduction of lymphocyte count 1 2.0 1 2.0 2 2.0 1.000 Reduction of platelet count 1 2.0 1 2.0 2 2.0 1.000 Test for bacteria (2) 0 0.0 1 2.0 1 1.0 1.000 Presence of glucose in urine 1 2.0 0 0.0 1 1.0 1.000 Presence of casts in urine 0 0.0 1 2.0 1 1.0 1.000 Increase of erythrocyte sedimentation 1 2.0 0 0.0 1 1.0 1.000 rate Increase of blood lactate 0 0.0 1 2.0 1 1.0 1.000 dehydrogenase level Increase of blood cholesterol 1 2.0 0 0.0 1 1.0 1.000 Increase of leukocyte count 0 0.0 1 2.0 1 1.0 1.000 Increase of erythrocyte count 1 2.0 0 0.0 1 1.0 1.000 Date Recue/Date Received 2022-04-06 Total in the organ system 25 50.0 23 46.0 48 48.0 0.689 Nervous system disorders (18 AE episodes) Headache 5 10.0 4 8.0 9 9.0 1.000 Somnolence 4 8.0 1 2.0 5 5.0 0.362 Dizziness 1 2.0 1 2.0 2 2.0 1.000 Total in the organ system 9 18.0 5 10.0 14 14.0 0.249 Musculoskeletal and connective tissue disorders (9 AE episodes) Pain in extremity 0 0.0 3 6.0 3 3.0 0.242 Myalgia 2 4.0 1 2.0 3 3.0 1.000 Arthralgia 0 0.0 1 2.0 1 1.0 1.000 Total in the organ system 2 4.0 5 10.0 7 7.0 0.436 Gastrointestinal disorders (5 AE episodes) Stomachache 0 0.0 3 6.0 3 3.0 0.242 Vomiting 1 2.0 1 2.0 2 2.0 1.000 Dryness in mouth 1 2.0 0 0.0 1 1.0 1.000 Total in the organ system 2 4.0 3 6.0 5 5.0 1.000 Respiratory, thoracic and mediastinal disorders (5 AE episodes) Nasal congestion 3 6.0 0 0.0 3 3.0 0.242 Oropharyngeal pain 0 0.0 1 2.0 1 1.0 1.000 Rhinorrhea 1 2.0 0 0.0 1 1.0 1.000 Total in the organ system 3 6.0 1 2.0 4 4.0 0.617 Date Recue/Date Received 2022-04-06 Infections and invasions (3 AE episodes) Rotavirus infection 1 2.0 0 0.0 1 1.0 1.000 Furunculus (3) 1 2.0 0 0.0 1 1.0 1.000 Enterovirus infection 0 0.0 1 2.0 1 1.0 1.000 Total in the organ system 2 4.0 1 2.0 3 3.0 1.000 Vascular disorders (3 AE episodes) Vaginal hemorrhage (4) 1 2.0 0 0.0 1 1.0 1.000 Haemorrhoids 1 2.0 0 0.0 1 1.0 1.000 Hyperemia 1 2,0 0 0.0 1 1.0 1.000 Total in the organ system 3 6.0 0 0.0 3 3.0 0.242 Metabolic disturbances (1 AE episode) Loss of appetite 1 2.0 0 0.0 1 1.0 1.000 Skin and subcutaneous tissue disorders (1 AE episode) Rash 0 0.0 1 2.0 1 1.0 1.000 Blood and lymphatic system disorders (1 AE episode) Leukopenia 0 0.0 1 2.0 1 1.0 1.000 Ear and labyrinth disorders (1 AE episode) Earache 1 2.0 0 0.0 1 1.0 1.000 Renal and urinary disorders (1 AE episode) Po I lakiuria 0 0.0 1 2.0 1 1.0 1.000 Psychiatric disorders (1 AE episode) Date Recue/Date Received 2022-04-06 Panic attack 0 0.0 1 2.0 1 1.0 1.000 Traumas, intoxications and procedure complications (1 AE episode) Food poisoning 1 2.0 0 0.0 1 1.0 1.000 Notes:
The results are given in the form: the number of subjects in whom adverse events (AE) were recorded, percentage from safety population in the given group.
Hypersensitivity at place of injection. PT "Tenderness" corresponds to PT
"Tenderness [10043224]".
2 PT "Test for bacteria" corresponds to LLT "Presence of bacteria in urine [10060857]".
"Furunculus" corresponds to LLT "Ear furunculus [10017556]", AE ¨ "Left ear auricle furunculus".
"Vaginal hemmorhage" corresponds to LLT "Bloody vaginal discharge {100498511".
During the study adverse events (AE) were observed in the following categories:
1) General disorders and administration site conditions - 76 AE:
1/10 of the dose: 35 cases 1/5 of the dose: 22 cases 2) Systemic reactions ¨54 AE
1/10 of the dose: 29 cases 1/5 of the dose: 25 cases 3) Laboratory deviations ¨ 76 AE
1/10 of the dose: 44 cases 1/5 of the dose: 32 cases.
The following AEs were connected with the preparation under study (as the connection assessment is "possible'', "probable" or "certain"): tenderness at place of injection, influenza Date Recue/Date Received 2022-04-06 like syndrome, fatigue, subfebrile temperature, hot flash, nasal congestion arose immediately after vaccine injection, headache, sore throat, cough, joint ache, general weakness, stomachache, panic attack, reduction of neutrophils, increase of bilirubin level.
For other AE the connection was determined as "doubtful" or "no connection".
No allergic reactions to the preparation under study were observed.
On the whole, once can say that adverse events revealed during the study are characteristic for most vaccine medicines. No cases of development of life-threatening adverse events were recorded.
Example 16 Determination of effectiveness of immunization of children with the developed pharmaceutical agent based on assessment of humoral immunity level.
95 children aged 12-18 years participated in the given study. The humoral immunity level was determined by assessing the titer of IgG antibodies specific to RBD domain of S protein of SARS-CoV-2 virus. The participants of the study were divided into two groups:
1) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of lx10I virus particles/1 ml, 47 people.
2) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of 2x1010 virus particles/1 ml, 48 people.
The samples of the same volunteers taken on Day 1 of the study before vaccination were used as the reference.
The titer of antigen-specific IgG in the first group was assessed on Days 21, 28 and 42 of the study and in the second group - on Days 21 and 28 of the study.
The titer of antibodies was determined by means of a test system for ELISA
that enables determining the titer of IgG to RBD domain of S antigen of SARS-CoV-2 virus.
The plates with pre-adsorbed RBD (100 ng/well) were washed 5 times Date Recue/Date Received 2022-04-06 with a washing buffer. Then, 100 ul of the positive control and 100 ul of the negative control were added to the plate wells in duplicate. A series of two-fold dilutions of the studied samples were added to other wells (two repeats per each sample). The plate was sealed with a film and incubated for an hour at +37 C while mixing at the rate of 300 rpm. Then the wells were washed with a working solution of the washing buffer. Then, 100 ul of the working solution of the conjugate of monoclonal antibodies were added to each well, the plate was sealed with an adhesive film and incubated for an hour at +37 C while mixing at the rate of 300 rpm. Then the wells were washed with a working solution of the washing buffer. Then, 100 ul of chromogen substrate solution were added to each well and incubated during 15 minutes in a dark place at a temperature from +20 C. After that, the reaction was stopped by adding 50 ul of a stop-reagent to each well (1M sulfuric acid solution). The result was determined during 10 minutes after reaction stop by measuring optical density on the spectrophotometer at the wave length of 450 nm.
The titer of IgG was detelinined as maximum serum dilution at which 0D450 serum value of an immunized participant exceeds the control serum value (serum of a participant before immunization) more than 2 times.
The results of determination of the titer of RBD-specific IgG antibodies in the first group (1x10' virus particles/dose) are given in Fig. 3. According to the provided data, the titer of antibodies specific to RBD-domain of S protein of SARS-Cov2 virus gradually increases after vaccination, achieving maximum value on Day 42. The reciprocal mean geometrical value at the given point is 13192. By Day 42 of the study seroconversion was observed in all 47 volunteers constituting the given group.
The results of determination of the titer of RBD-specific IgG antibodies in the second group (2x101 virus particles/dose) are shown in Fig.4. As it can be seen from the provided data, the titer of antibodies specific to RBD-domain of SARS-Cov2 virus S
protein gradually increases after vaccination with 1/5th of the full therapeutical dose of the vaccine for adults, achieving the maximum value on Day 42. The reciprocal mean geometrical value at the given point is 19292. By Day 42 of the study seroconversion was observed in all 49 volunteers constituting the given group.
Thus, the results of the conducted study showed that vaccination of children with the developed inununobiological agent is capable of inducing formation of high-level post-vaccination humoral immunity.
Date Recue/Date Received 2022-04-06 Example 15 Determination of effectiveness of immunization of children with the developed pharmaceutical agent based on assessment of cell immunity level.
95 children aged 12-18 years participated in the given study. The participants of the study were divided into two groups:
1) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of lx101 virus particles/1 ml, 47 people.
2) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of 2x10' virus particles/1 ml, 48 people.
Cell immunity level was determined by assessing the quantity of proliferating CD4+ and CD8+ lymphocytes of volunteers' peripheral blood in in vitro culture after repeated cell restimulation with recombinant S protein of SARS-CoV-2. Before immunization as well as after 28 days the patients' blood samples were drawn from which mononuclear cells were isolated by centrifugation in the ficoll solution density gradient (1.077 g/mL; PanEco). Then, the isolated cells were colored with the fluorescent dye CFSE (Invivogen, USA) and seeded on wells of a 96-well plate (2* 105 cells/well). The repeated stimulation of lymphocytes was carried out in in vitro conditions by adding coronavirus S protein to the culture medium (final protein concentration I gimp. Intact cells to which the antigen was not added were used as the negative control. In 72 hours after antigen addition % of proliferating cells was measured and the cultural medium was taken for measuring gamma interferon quantity.
To determine % of proliferating cells they were stained with antibodies to marker molecules of T lymphocytes CD3, CD4, CD8 (anti-CD3 Pe-Cy7 (BDBiosciences, SK7 clone), anti-CD4 APC (BDBiosciences, SK3 clone), anti-CD8 PerCP-Cy5.5 (BDBiosciences, SKI
clone)). Proliferating (with a lower quantity of cell colorant CFSE) CD4+ and CD8+ T
lymphocytes were determined in the cell mixture with the use of the flow cytofluorometer BD
FACS Arian (BD Biosciences, USA). The resultant percentage of proliferating cells in each Date Recue/Date Received 2022-04-06 sample was determined by deducing the result obtained during analysis of intact cells from the result obtained during analysis of cells restimulated with coronavirus S
protein antigen.
The results (with conducted statistical processing) of determination of the percentage of proliferating CD4+ and CD8+ T lymphocytes on Day 1 (before immunization) and on Day 28 of the study are given in Fig. 5 and Fig. 6.
The obtained data showed that immunization of children with the developed agent with both selected doses makes it possible to reliably increase the percentage of proliferating CD4+
and CD8+ T lymphocytes after antigen restimulation on Day 28 after immunization.
Based on the obtained data, one can conclude that double vaccination of children with the developed immunological agent is capable of inducing formation of high-level post-vaccination cell immunity.
Thus, the provided examples confirm that as a result of conducted work a safe and effective agent was created that induced development of reactions of humoral and cell immune response against SARS-CoV-2 virus in children aged 1 month and older.
Industrial applicability All provided examples support effectiveness of the developed agents that effectively induce immune response against SARS-CoV-2 virus in children aged 1 month and older and industrial applicability.
Date Recue/Date Received 2022-04-06
method. To do that:
I. The antigen was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted by the method of 2-fold dilutions. In total, 12 dilutions of each sample were prepared.
4, 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of IgG antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 5.
Date Recue/Date Received 2022-04-06 Table 5¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG antibodies 1 Ad26-CMV-S-CoV2, i/m 696 2 Ad26-CAG-S-CoV2, i/m 528 3 Ad26-EF1-S-CoV2 i/m 459 4 Ad5-CMV-S-CoV2, i/m 9701 Ad5-CAG-S-CoV2, i/m 11143 6 Ad5-EF1-S-CoV2, i/m 14703 7 simAd25-CMV-S-CoV2, i/m 3676 8 simAd25-CAG-S-CoV2, i/m 5572 9 simAd25-EF1-S-CoV2, i/m 3676 Ad26-CMV-S-CoV2, i/n 230 11 Ad26-CAG-S-CoV2, i/n 200 12 Ad26-EF1-S-CoV2, i/n 174 Date Recue/Date Received 2022-04-06 Group of animals Titer of IgG antibodies 13 Ad5-CMV-S-CoV2, 606 14 Ad5-CAG-S-CoV2, i/n 459 15 Ad5-EF I -S-CoV2, i/n 459 16 simAd25-CMV-S-CoV2, i/n 459 17 simAd25-CAG-S-CoV2, i/n 400 18 simAd25-EF1-S-CoV2, i/n 303 Based on the given data, single immunization with the developed agent induces humoral immune response to SARS-CoV-2 glycoprotein.
Example 12 Study of immunogenicity of the developed agent upon administration to young animals in different doses.
The aim of the given study was assessment of humoral immune response to S
protein of SARS-CoV-2 with administration of the developed agent in different doses to young animals.
Young mice of C57/B16 line (3-4 weeks) were used to study immunogenicity of the developed agent. The animals were distributed by groups of 5 to whom the following agents were administered intramuscularly, twice, with an interval of 28 days:
1) Ad5-CMV-S-CoV2, 5*109vp/100 ul, 2) Ad5-CMV-S-CoV2, 10'0vp/100 ul, 3) Ad5-CMV-S-CoV2, 5*101 vp/100 ul.
Date Recue/Date Received 2022-04-06 In 21 days the animals' blood was drawn, blood serum was isolated and the titer of IgG antibodies to S protein of SARS-CoV-2 coronavirus was determined by the ELISA
method. To do that:
1. The antigen was adsorbed on the wells of a 96-well plate for ELISA
during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted 100 times and then by the method of 2-fold dilutions. In total, 12 dilutions of each sample were prepared.
4. 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 6.
Date Recue/Date Received 2022-04-06 Table 6¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG antibodies 1 Ad5-CMV-S-CoV2, 5*109vp/100 ul, 22286 2 Ad5-CMV-S-CoV2, 101 vp/100 ul, 44572 3 Ad5-CMV-S-CoV2, 5*101 vp/100 ul. 117627 Based on the given data, the developed agent demonstrates immunogenicity within the whole range of selected doses.
Example 13 Study of immunogenicity of the developed agent on young mice with different administration protocols.
Young mice of C57/B16 line (3-4 weeks) were used to study immunogenicity of the developed agent. The animals were distributed by groups of 5 and the following agents were administered to them:
1) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
2) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2i/m, 109vp/100 ul;
3) Ad26-CMV-S-CoV2, i/n, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2i/m, 109vp/100 ul;
4) Ad26-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks simAd5-CMV-S-CoV2i/m, 109vp/100 ul;
Date Recue/Date Received 2022-04-06 5) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd5-CMV-S-CoV2 i/m, l0svp/100 ul;
6) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
7) Ad5-CMV-S-CoV2, i/n, 109vp/100 ul; in 3 weeksAd26-CMV-S-CoV2i/m, 109vp/100 ul;
8) Ad5-CMV-S-CoV2, i/m, 109vp/100 ul;in 3 weekssimAd5-CMV-S-CoV2i/m, 109vp/100 ul;
9) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weekssimAd5-CMV-S-CoV2i/m, 109vp/100 ul;
10) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks Ad5-CMV-S-CoV2 i/m, 109vp/100 ul;
11) simAd25-CMV-S-CoV2, i/m, 109vp/100 ul; in 3 weeks Ad26-CMV-S-CoV2, i/m, 109vp/100 ul.
In 21 days the animals' blood was drawn, blood serum was isolated and the titer of IgG antibodies to S protein of SARS-CoV-2 coronavirus was determined by the ELISA
method. To do that:
1. The antigen was adsorbed on the wells of a 96-well plate for ELISA during 16 hours at +4 C.
2. The, to get rid of non-specific binding, 5 % milk in TPBS 100 ul/well was added to the plate wells. It was incubated on a shaker at 37 C for an hour.
3. The serum samples of immunized mice were diluted by the method of 2-fold dilutions.
In total, 12 dilutions of each sample were prepared.
4. 50 ul of each diluted serum sample were added to the plate wells.
5. Then, the samples were incubated for an hour at 37 C.
6. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
Date Recue/Date Received 2022-04-06 7. The secondary antibodies to mouse immunoglobulins conjugated with horseradish peroxidase were added.
8. Then, the samples were incubated for an hour at 37 C.
9. The incubation was followed by three-fold washing of the wells with a phosphate buffer.
10. Then tetramethylbenzidine (TMB) was added, which is a horseradish peroxidase substrate and as a result of the reaction converts to a colored compound.
11. The reaction was stopped in 15 minutes by adding sulfuric acid. Then, using a spectrophotometer, the optical density (OD) of the solution in each well was measured at the wavelength of 450 nm.
The titer of antibodies was determined as the latest dilution in which the optical density of the solution was reliably higher than in the negative control group. The obtained results (mean geometrical value) are given in Table 7.
Table 7 ¨ Titer Of Igg Antibodies To S Protein In Blood Serum Of Mice (Mean Geometrical Value Of The Titer Of Antibodies) Group of animals Titer of IgG
antibodies 1 Ad26-CMV-S-CoV2 i/m, Ad26-CMV-S-CoV2 i/m 11143 2 Ad26-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 29407 3 Ad26-CMV-S-CoV2, i/n, Ad5-CMV-S-CoV2 22286 4 Ad26-CMV-S-CoV2, simAd5-CMV-S-CoV2 i/m, 14703 Ad5-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 16890 6 Ad5-CMV-S-CoV2, i/m, Ad26-CMV-S-CoV2 i/m, 33779 7 Ad5-CMV-S-CoV2, i/n, Ad26-CMV-S-CoV2 i/m, 25600 Date Recue/Date Received 2022-04-06 Group of animals Titer of IgG
antibodies 8 Ad5-CMV-S-CoV2, i/m, sirnAd5-CMV-S-CoV2 i/m, 14703 9 simAd5-CMV-S-CoV2, i/m, simAd5-CMV-S-CoV2 i/m, 12800 simAd5-CMV-S-CoV2, i/m, Ad5-CMV-S-CoV2 i/m, 16890 11 simAd5-CMV-S-CoV2, Ad26-CMV-S-CoV2, i/m 14703 The obtained results demonstrate that the developed agent provides for development of humoral immune response against SARS-CoV-2 in young animals with different administration protocols.
Example 14 Study of utilization of the developed agent for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 for children.
100 volunteers aged 12-17 years participated in the given study. The suggested immunization protocol included sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent according to variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2). One volunteer discontinued participation before administration of component 1 because of newly diagnosed hypertension, correspondingly, 99 volunteers started the therapy under study. Component 2 was not administered to: 1 person ¨ because of non-attendance, 1 person - because of an adverse event (leukopenia), 1 person - because of an intestinal infection of unknown etiology (of enteroviral type), 1 person - because of hospitalization with a purulent furunculus in 5 days after administration of the component, 1 person - because of hospitalization (an intestinal infection) and 1 person - because of COVID, 2 people - refused to participate. Correspondingly, both vaccine components were received by 91 volunteers.
205 AEs that developed in 73 volunteers (73.0%) after vaccine administration were recorded. Table 8 includes the number (share) of volunteers with presence of AE in each group by the system organ class (SOC) and preferred term (PT) according to the MedDRA dictionary, as well as by connection with the preparation under study and severity degree.
The intergroup comparison of the frequency of AE development was conducted by means of x2-test and, if Date Recue/Date Received 2022-04-06 required, Fisher exact test, if the expected frequency in any of the cells was below 5. The analysis did not reveal statistically significant differences by the frequency of individual AE
between the groups.
Table 8. Adverse Events Recorded During The Analyzed Period By System Organ Classes, Preferred Terms And Groups (FAS-Population) Group 1 Group 2 Total (dose 1/10) .. (dose 1/5) N = 100 P-Description N=50 N=50 value N % N % N %
Any PT 37 74.0 36 72.0 73 73.0 0.822 General disorders and reactions at the place of administration (78 AE
episodes) Pain at place of injection 15 30.0 11 22.0 26 26.0 0.362 Tenderness (1) 7 14.0 7 14.0 14 14.0 1.000 Hyperthermia 5 10.0 3 6.0 8 8.0 0.715 Influenza like illness 3 6.0 5 10.0 8 8.0 0.715 Erythema at place of injection 4 8.0 0 0.0 4 4.0 0.117 Itching at place of injection 1 2.0 0 0.0 1 1.0 1.000 Local temperature increase at place of 1 2.0 0 0.0 1 1.0 1.000 administration Shivering 1 2.0 0 0.0 1 1.0 1.000 Edema at place of injection 1 2.0 0 0.0 1 1.0 1.000 Pyrexia 0 0.0 1 2.0 1 1.0 1.000 Date Recue/Date Received 2022-04-06 Total in the organ system 29 58.0 23 46.0 52 52.0 0.230 Laboratory and instrumental data (76 AE episodes) Reduction of neutrophil count 17 34.0 18 36.0 35 35.0 0.834 Positive result of urine analysis for 8 16.0 5 10.0 13 13.0 0.372 erythrocytes Increase of blood bilirubin level 3 6.0 2 4.0 5 5.0 1.000 Presence of protein in urine 1 2.0 2 4.0 3 3.0 1.000 Reduction of hemoglobin level 1 2,0 2 4.0 3 3.0 1.000 Presence of leukocytes in urine 1 2.0 1 2.0 2 2.0 1.000 Increase of blood alkaline phosphatase 1 2.0 1 2.0 2 2.0 1.000 Reduction of lymphocyte count 1 2.0 1 2.0 2 2.0 1.000 Reduction of platelet count 1 2.0 1 2.0 2 2.0 1.000 Test for bacteria (2) 0 0.0 1 2.0 1 1.0 1.000 Presence of glucose in urine 1 2.0 0 0.0 1 1.0 1.000 Presence of casts in urine 0 0.0 1 2.0 1 1.0 1.000 Increase of erythrocyte sedimentation 1 2.0 0 0.0 1 1.0 1.000 rate Increase of blood lactate 0 0.0 1 2.0 1 1.0 1.000 dehydrogenase level Increase of blood cholesterol 1 2.0 0 0.0 1 1.0 1.000 Increase of leukocyte count 0 0.0 1 2.0 1 1.0 1.000 Increase of erythrocyte count 1 2.0 0 0.0 1 1.0 1.000 Date Recue/Date Received 2022-04-06 Total in the organ system 25 50.0 23 46.0 48 48.0 0.689 Nervous system disorders (18 AE episodes) Headache 5 10.0 4 8.0 9 9.0 1.000 Somnolence 4 8.0 1 2.0 5 5.0 0.362 Dizziness 1 2.0 1 2.0 2 2.0 1.000 Total in the organ system 9 18.0 5 10.0 14 14.0 0.249 Musculoskeletal and connective tissue disorders (9 AE episodes) Pain in extremity 0 0.0 3 6.0 3 3.0 0.242 Myalgia 2 4.0 1 2.0 3 3.0 1.000 Arthralgia 0 0.0 1 2.0 1 1.0 1.000 Total in the organ system 2 4.0 5 10.0 7 7.0 0.436 Gastrointestinal disorders (5 AE episodes) Stomachache 0 0.0 3 6.0 3 3.0 0.242 Vomiting 1 2.0 1 2.0 2 2.0 1.000 Dryness in mouth 1 2.0 0 0.0 1 1.0 1.000 Total in the organ system 2 4.0 3 6.0 5 5.0 1.000 Respiratory, thoracic and mediastinal disorders (5 AE episodes) Nasal congestion 3 6.0 0 0.0 3 3.0 0.242 Oropharyngeal pain 0 0.0 1 2.0 1 1.0 1.000 Rhinorrhea 1 2.0 0 0.0 1 1.0 1.000 Total in the organ system 3 6.0 1 2.0 4 4.0 0.617 Date Recue/Date Received 2022-04-06 Infections and invasions (3 AE episodes) Rotavirus infection 1 2.0 0 0.0 1 1.0 1.000 Furunculus (3) 1 2.0 0 0.0 1 1.0 1.000 Enterovirus infection 0 0.0 1 2.0 1 1.0 1.000 Total in the organ system 2 4.0 1 2.0 3 3.0 1.000 Vascular disorders (3 AE episodes) Vaginal hemorrhage (4) 1 2.0 0 0.0 1 1.0 1.000 Haemorrhoids 1 2.0 0 0.0 1 1.0 1.000 Hyperemia 1 2,0 0 0.0 1 1.0 1.000 Total in the organ system 3 6.0 0 0.0 3 3.0 0.242 Metabolic disturbances (1 AE episode) Loss of appetite 1 2.0 0 0.0 1 1.0 1.000 Skin and subcutaneous tissue disorders (1 AE episode) Rash 0 0.0 1 2.0 1 1.0 1.000 Blood and lymphatic system disorders (1 AE episode) Leukopenia 0 0.0 1 2.0 1 1.0 1.000 Ear and labyrinth disorders (1 AE episode) Earache 1 2.0 0 0.0 1 1.0 1.000 Renal and urinary disorders (1 AE episode) Po I lakiuria 0 0.0 1 2.0 1 1.0 1.000 Psychiatric disorders (1 AE episode) Date Recue/Date Received 2022-04-06 Panic attack 0 0.0 1 2.0 1 1.0 1.000 Traumas, intoxications and procedure complications (1 AE episode) Food poisoning 1 2.0 0 0.0 1 1.0 1.000 Notes:
The results are given in the form: the number of subjects in whom adverse events (AE) were recorded, percentage from safety population in the given group.
Hypersensitivity at place of injection. PT "Tenderness" corresponds to PT
"Tenderness [10043224]".
2 PT "Test for bacteria" corresponds to LLT "Presence of bacteria in urine [10060857]".
"Furunculus" corresponds to LLT "Ear furunculus [10017556]", AE ¨ "Left ear auricle furunculus".
"Vaginal hemmorhage" corresponds to LLT "Bloody vaginal discharge {100498511".
During the study adverse events (AE) were observed in the following categories:
1) General disorders and administration site conditions - 76 AE:
1/10 of the dose: 35 cases 1/5 of the dose: 22 cases 2) Systemic reactions ¨54 AE
1/10 of the dose: 29 cases 1/5 of the dose: 25 cases 3) Laboratory deviations ¨ 76 AE
1/10 of the dose: 44 cases 1/5 of the dose: 32 cases.
The following AEs were connected with the preparation under study (as the connection assessment is "possible'', "probable" or "certain"): tenderness at place of injection, influenza Date Recue/Date Received 2022-04-06 like syndrome, fatigue, subfebrile temperature, hot flash, nasal congestion arose immediately after vaccine injection, headache, sore throat, cough, joint ache, general weakness, stomachache, panic attack, reduction of neutrophils, increase of bilirubin level.
For other AE the connection was determined as "doubtful" or "no connection".
No allergic reactions to the preparation under study were observed.
On the whole, once can say that adverse events revealed during the study are characteristic for most vaccine medicines. No cases of development of life-threatening adverse events were recorded.
Example 16 Determination of effectiveness of immunization of children with the developed pharmaceutical agent based on assessment of humoral immunity level.
95 children aged 12-18 years participated in the given study. The humoral immunity level was determined by assessing the titer of IgG antibodies specific to RBD domain of S protein of SARS-CoV-2 virus. The participants of the study were divided into two groups:
1) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of lx10I virus particles/1 ml, 47 people.
2) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of 2x1010 virus particles/1 ml, 48 people.
The samples of the same volunteers taken on Day 1 of the study before vaccination were used as the reference.
The titer of antigen-specific IgG in the first group was assessed on Days 21, 28 and 42 of the study and in the second group - on Days 21 and 28 of the study.
The titer of antibodies was determined by means of a test system for ELISA
that enables determining the titer of IgG to RBD domain of S antigen of SARS-CoV-2 virus.
The plates with pre-adsorbed RBD (100 ng/well) were washed 5 times Date Recue/Date Received 2022-04-06 with a washing buffer. Then, 100 ul of the positive control and 100 ul of the negative control were added to the plate wells in duplicate. A series of two-fold dilutions of the studied samples were added to other wells (two repeats per each sample). The plate was sealed with a film and incubated for an hour at +37 C while mixing at the rate of 300 rpm. Then the wells were washed with a working solution of the washing buffer. Then, 100 ul of the working solution of the conjugate of monoclonal antibodies were added to each well, the plate was sealed with an adhesive film and incubated for an hour at +37 C while mixing at the rate of 300 rpm. Then the wells were washed with a working solution of the washing buffer. Then, 100 ul of chromogen substrate solution were added to each well and incubated during 15 minutes in a dark place at a temperature from +20 C. After that, the reaction was stopped by adding 50 ul of a stop-reagent to each well (1M sulfuric acid solution). The result was determined during 10 minutes after reaction stop by measuring optical density on the spectrophotometer at the wave length of 450 nm.
The titer of IgG was detelinined as maximum serum dilution at which 0D450 serum value of an immunized participant exceeds the control serum value (serum of a participant before immunization) more than 2 times.
The results of determination of the titer of RBD-specific IgG antibodies in the first group (1x10' virus particles/dose) are given in Fig. 3. According to the provided data, the titer of antibodies specific to RBD-domain of S protein of SARS-Cov2 virus gradually increases after vaccination, achieving maximum value on Day 42. The reciprocal mean geometrical value at the given point is 13192. By Day 42 of the study seroconversion was observed in all 47 volunteers constituting the given group.
The results of determination of the titer of RBD-specific IgG antibodies in the second group (2x101 virus particles/dose) are shown in Fig.4. As it can be seen from the provided data, the titer of antibodies specific to RBD-domain of SARS-Cov2 virus S
protein gradually increases after vaccination with 1/5th of the full therapeutical dose of the vaccine for adults, achieving the maximum value on Day 42. The reciprocal mean geometrical value at the given point is 19292. By Day 42 of the study seroconversion was observed in all 49 volunteers constituting the given group.
Thus, the results of the conducted study showed that vaccination of children with the developed inununobiological agent is capable of inducing formation of high-level post-vaccination humoral immunity.
Date Recue/Date Received 2022-04-06 Example 15 Determination of effectiveness of immunization of children with the developed pharmaceutical agent based on assessment of cell immunity level.
95 children aged 12-18 years participated in the given study. The participants of the study were divided into two groups:
1) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of lx101 virus particles/1 ml, 47 people.
2) sequential intramuscular administration of component 1 and component 2 of the pharmaceutical agent by variant 1 (Ad26-CMV-S-CoV2, Ad5-CMV-S-CoV2) in the dose of 2x10' virus particles/1 ml, 48 people.
Cell immunity level was determined by assessing the quantity of proliferating CD4+ and CD8+ lymphocytes of volunteers' peripheral blood in in vitro culture after repeated cell restimulation with recombinant S protein of SARS-CoV-2. Before immunization as well as after 28 days the patients' blood samples were drawn from which mononuclear cells were isolated by centrifugation in the ficoll solution density gradient (1.077 g/mL; PanEco). Then, the isolated cells were colored with the fluorescent dye CFSE (Invivogen, USA) and seeded on wells of a 96-well plate (2* 105 cells/well). The repeated stimulation of lymphocytes was carried out in in vitro conditions by adding coronavirus S protein to the culture medium (final protein concentration I gimp. Intact cells to which the antigen was not added were used as the negative control. In 72 hours after antigen addition % of proliferating cells was measured and the cultural medium was taken for measuring gamma interferon quantity.
To determine % of proliferating cells they were stained with antibodies to marker molecules of T lymphocytes CD3, CD4, CD8 (anti-CD3 Pe-Cy7 (BDBiosciences, SK7 clone), anti-CD4 APC (BDBiosciences, SK3 clone), anti-CD8 PerCP-Cy5.5 (BDBiosciences, SKI
clone)). Proliferating (with a lower quantity of cell colorant CFSE) CD4+ and CD8+ T
lymphocytes were determined in the cell mixture with the use of the flow cytofluorometer BD
FACS Arian (BD Biosciences, USA). The resultant percentage of proliferating cells in each Date Recue/Date Received 2022-04-06 sample was determined by deducing the result obtained during analysis of intact cells from the result obtained during analysis of cells restimulated with coronavirus S
protein antigen.
The results (with conducted statistical processing) of determination of the percentage of proliferating CD4+ and CD8+ T lymphocytes on Day 1 (before immunization) and on Day 28 of the study are given in Fig. 5 and Fig. 6.
The obtained data showed that immunization of children with the developed agent with both selected doses makes it possible to reliably increase the percentage of proliferating CD4+
and CD8+ T lymphocytes after antigen restimulation on Day 28 after immunization.
Based on the obtained data, one can conclude that double vaccination of children with the developed immunological agent is capable of inducing formation of high-level post-vaccination cell immunity.
Thus, the provided examples confirm that as a result of conducted work a safe and effective agent was created that induced development of reactions of humoral and cell immune response against SARS-CoV-2 virus in children aged 1 month and older.
Industrial applicability All provided examples support effectiveness of the developed agents that effectively induce immune response against SARS-CoV-2 virus in children aged 1 month and older and industrial applicability.
Date Recue/Date Received 2022-04-06
Claims (15)
1. Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
2. Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ
ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
3. Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID
NO:1, SEQ
ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
NO:1, SEQ
ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 5 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
4. Utilization of an agent comprising a component in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID
NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
5. Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant human adenovirus serotype 26 in which El and E3 sites were deleted, while ORF6-Ad26 site was replaced with ORF6-Ad5 with an integrated expression cassette selected from SEQ ID
NO:1, SEQ
Date Recue/Date Received 2022-04-06 ID NO:2, SEQ ID NO:3, and component 2 in the foiiii of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID
NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
NO:1, SEQ
Date Recue/Date Received 2022-04-06 ID NO:2, SEQ ID NO:3, and component 2 in the foiiii of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID
NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
6. Utilization of an agent comprising a combination representing component 1 in the form of an expression vector based on the genome of recombinant simian adenovirus serotype 25 with deleted El and E3 sites with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and component 2 in the form of an expression vector based on the genome of recombinant hurnan adenovirus serotype 5 with deleted E 1 and E3 sites with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
7. Utilization presented herein in claims 1-6 wherein the agent enables induction of mucosal immune response on mucous membranes of the respiratory tract.
8. Utilization presented herein in claims 1-6 wherein the agent is prepared in a liquid or lyophilized form.
9. Utilization presented herein in claim 8 wherein the liquid form of the agent contains a buffer, wt. %:
Tris 0.1831 0.3432 Sodium chloride 0.3313 ... 0.6212 Sucrose 3.7821 .. 7.0915 Magnesium chloride hexahydrate 0.0154 ... 0.0289 EDTA 0.0029 ... 0.0054 Polysorbate-80 0.0378 ... 0.0709 Ethanol 95% 0.0004 ... 0.0007 5'7 Date Recue/Date Received 2022-04-06 Water rest.
Tris 0.1831 0.3432 Sodium chloride 0.3313 ... 0.6212 Sucrose 3.7821 .. 7.0915 Magnesium chloride hexahydrate 0.0154 ... 0.0289 EDTA 0.0029 ... 0.0054 Polysorbate-80 0.0378 ... 0.0709 Ethanol 95% 0.0004 ... 0.0007 5'7 Date Recue/Date Received 2022-04-06 Water rest.
10. Utilization presented herein in claim 8 wherein the reduced lyophilized form of the agent contains a buffer, wt. %:
Tris 0.0180 ... 0.0338 Sodium chloride 0.1044 ... 0.1957 Sucrose 5.4688 ... 10.2539 Magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 Polysorbate-80 0.0037 ... 0.0070 Water rest,
Tris 0.0180 ... 0.0338 Sodium chloride 0.1044 ... 0.1957 Sucrose 5.4688 ... 10.2539 Magnesium chloride hexahydrate 0.0015 ... 0.0028 EDTA 0.0003 ... 0.0005 Polysorbate-80 0.0037 ... 0.0070 Water rest,
11. Utilization presented herein in claims 1-10 wherein the component and/or components of the agent are intended for intranasal and/or intramuscular administration.
12. Utilization presented herein in claims 1-10 wherein the agent is intended for administration in the dose of 5*109- 5*1010 virus particles.
13. Utilization presented herein in claims 3, 5, 6, 9, 10 wherein the components of the agent are intended for sequential administration with an interval of over 1 week.
14. Utilization presented herein in claims 3, 5, 6, 9, 10 wherein the components of the agent are intended for simultaneous administration.
15. Utilization presented herein in claims 3, 5, 6, 9, 10 wherein the components are in different packages.
Date Recue/Date Received 2022-04-06
Date Recue/Date Received 2022-04-06
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021134724A RU2761904C1 (en) | 2021-11-26 | 2021-11-26 | Drug application for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children |
| RU2021134724 | 2021-11-26 | ||
| PCT/RU2022/000047 WO2022197209A1 (en) | 2021-11-26 | 2022-02-18 | Induction of immunity to sars-cov-2 in children |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3156264A1 true CA3156264A1 (en) | 2022-10-24 |
Family
ID=81845591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3156264A Abandoned CA3156264A1 (en) | 2021-11-26 | 2022-02-18 | Utilization of an agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2023512381A (en) |
| CN (1) | CN116528895A (en) |
| CA (1) | CA3156264A1 (en) |
| IL (1) | IL291816B1 (en) |
| MX (1) | MX2022004059A (en) |
| ZA (1) | ZA202203566B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2731342C9 (en) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments) |
-
2022
- 2022-02-18 CN CN202280000642.4A patent/CN116528895A/en active Pending
- 2022-02-18 MX MX2022004059A patent/MX2022004059A/en unknown
- 2022-02-18 JP JP2022520203A patent/JP2023512381A/en active Pending
- 2022-02-18 CA CA3156264A patent/CA3156264A1/en not_active Abandoned
- 2022-03-28 ZA ZA2022/03566A patent/ZA202203566B/en unknown
- 2022-03-30 IL IL291816A patent/IL291816B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022004059A (en) | 2022-10-18 |
| CN116528895A (en) | 2023-08-01 |
| IL291816A (en) | 2022-06-01 |
| IL291816B1 (en) | 2024-03-01 |
| ZA202203566B (en) | 2023-11-29 |
| JP2023512381A (en) | 2023-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2720614C1 (en) | Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | |
| US11547673B1 (en) | Coronavirus vaccine | |
| Sui et al. | Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques | |
| WO2021076010A1 (en) | Pharmaceutical agent for inducing specific immunity against sars-cov-2 | |
| RU2743963C1 (en) | Agent for induction of specific immunity against severe acute respiratory syndrome coronavirus (sars-cov-2) in liquid form (versions) | |
| CA3156264A1 (en) | Utilization of an agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children | |
| US20220249655A1 (en) | Agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in lyophilized form (variants) | |
| JP7369276B2 (en) | Expression vector for severe acute respiratory syndrome virus SARS-COV-2 | |
| WO2022197209A1 (en) | Induction of immunity to sars-cov-2 in children | |
| RU2709659C1 (en) | Immunobiological agent and a method for use thereof for inducing specific immunity to the middle eastern respiratory syndrome virus (versions) | |
| EA043182B1 (en) | APPLICATION OF A DRUG FOR INDUCING SPECIFIC IMMUNE AGAINST SARS-COV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN CHILDREN | |
| JP7360544B2 (en) | Pharmaceutical products for inducing specific immunity against SARS-COV-2 | |
| US20220265816A1 (en) | Use of the agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 for revaccination of population (variants) | |
| RU2811791C1 (en) | Expression vector based on human adenovirus 19 serotype and method of its application | |
| EA042672B1 (en) | APPLICATION OF A DRUG FOR INDUCING SPECIFIC IMMUNE AGAINST THE SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN PERSONS OVER 60 AND/OR HAVING CHRONIC DISEASES (OPTIONS) | |
| Garg et al. | Vaccine-induced immune responses against SARS-CoV-2 infections | |
| WO2022177466A1 (en) | The use of the agent for inducing immunity to sars-cov-2 | |
| EA043101B1 (en) | MEANS FOR INDUCING SPECIFIC IMMUNE AGAINST SARS-COV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN LIQUID FORM (VERSIONS) | |
| JP2023507543A (en) | Use of Agents (Variations) to Induce Specific Immunity Against Severe Acute Respiratory Syndrome Virus SARS-CoV-2 in Subjects Over 60 Years of Age and/or with Chronic Diseases | |
| Ramasamy | COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract. Viruses 2023, 15, 2203 | |
| EA042634B1 (en) | MEANS FOR INDUCING SPECIFIC IMMUNE AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN LYOPHILIZED FORM (VERSIONS) | |
| EA043163B1 (en) | APPLICATION OF MEANS FOR INDUCING SPECIFIC IMMUNE AGAINST SARS-COV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS FOR POPULATION REVACCINATION (VERSIONS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230922 |